Gemtuzumab Ozogamicin (MYLOTARG ™)
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 1
A SINGLE ARM, OPEN-LABEL, PHASE 4 STUDY EVALUATING QT INTERVAL, 
PHARMACOKINETICS, AND SAFETY OF GEMTUZUMAB OZOGAMICIN 
(MYLOTARG ™™) AS A SINGLE-AGENT REGIMEN IN PATIENTS WITH 
RELAPSED OR REFRACTORY CD33-POSITIVE ACUTE MYELOID LE[LOCATION_006]EMIA
Investigational Product Number: PF-05208747 (CMA-676)
Investigational Product Name: [CONTACT_421950] (MYLOTARG™)
[LOCATION_002] (US) Investigational New 
Drug (IND) Number:
European Clinical Trials Database 
(EudraCT) Number:2018-002619-89
Protocol Number: B1761031
Phase: 4
This document and accompanying materials contain confidential information belonging to [COMPANY_007].  Except as 
otherwise agreed to in writing, by [CONTACT_22788], you agree to hold this information in 
confidence and not copy or disclose it to others (except where required by [CONTACT_1289]) or use it for 
unauthorized purposes.  In the event of any actual or suspected breach of this obligation, [COMPANY_007] must be promptly notified.CCI
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 2Document History
Document Version Date Summary of Changes and Rationale
Final Protocol 27June 2018 Not applicable (N/A)
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, [ADDRESS_532532] OF FIGURES ................................ ................................ ................................ ................... 7
APPENDI CES ................................ ................................ ................................ ........................... 7
PROTOCOL  SUMMARY ................................ ................................ ................................ ......... 8
SCHEDUL E OF ACTIVITI ES................................ ................................ ................................ 12
1. INTRODUCTION ................................ ................................ ................................ ............... 18
1.1. Mechanism of Action/I ndication ................................ ................................ ............. 18
1.2. Background and Rationale ................................ ................................ ...................... 18
1.2.1. I ncidence and Treatment of Acute M yeloid Leukemia (AML) .................. 18
1.2.2. Gemtuzumab Ozogamicin for Treatment of Acute M yeloid 
Leukemia ................................ ................................ ................................ .......... 19
[IP_ADDRESS]. Regulatory  History ................................ ................................ ....19
[IP_ADDRESS]. Fractionated Dosing of GO ................................ ....................... 20
[IP_ADDRESS]. Pharmacod ynam ics, Pharmacokinetics and Dosage ................. 20
[IP_ADDRESS]. Clinical Data for GO in Patients with AML in First 
Relapse ................................ ................................ .............................. 21
[IP_ADDRESS]. Study  Rationale ................................ ................................ ......... 21
2.STUDY OBJECTIVES AND ENDPOINTS ................................ ................................ .......23
3. STUDY DESIGN ................................ ................................ ................................ ................. 23
4. PATI ENT ELIGI BILITY CRI TERIA ................................ ................................ ................. 25
4.1. I nclusion Criteria ................................ ................................ ................................ .....25
4.2. Exclusion Criteria................................ ................................ ................................ ....26
4.3. L ifesty le Requirements ................................ ................................ ........................... 27
4.3.1. Contraception ................................ ................................ .............................. 27
4.4. Sponsor’s Qualified Medica l Personnel ................................ ................................ ..[ADDRESS_532533] Supplies ................................ ................................ ............. 29
5.3.1. Dosage Form(s) and Packaging..................................................................29
5.4. Administration ................................ ................................ ................................ ......... 30
5.4.1. Administration of the Premedication ................................ .......................... 30
Gemtuzumab Ozogamicin (MYLOTARG ™)
B1761031
Protocol, [ADDRESS_532534] Supplies ........................................33
5.7. Concomitant Treatment(s).......................................................................................33
6. STUDY PROCEDURES .....................................................................................................33
6.1. Screening................................................................................................................. 33
6.2. Study Period ............................................................................................................35
6.2.1. GO Treatment .............................................................................................356.2.2. Cycle 1 ........................................................................................................36
[IP_ADDRESS]. Cycle 1 Day 1 (GO Treatment) .................................................36
[IP_ADDRESS]. Cycle 1 Day 4 and Day 7 (GO Treatment)................................37
[IP_ADDRESS]. Cycle 1 Day 10 (Post-GO Period).............................................[IP_ADDRESS]. Cycle 1 Days 15 and 21 (Post-GO Period) ...............................38
6.2.3. Cycle 2 ........................................................................................................39
[IP_ADDRESS]. Cycle 2 Day 1............................................................................39
[IP_ADDRESS]. Cycle 2 Day 4 and Day 7 (GO Treatment)................................40
[IP_ADDRESS]. Cycle 2 Day 10 (Post-GO Period).............................................[IP_ADDRESS]. Cycle 2 Days 15 and 21 (Post-GO Period) ...............................40
6.2.4. The End-of-Treatment (EOT) Visit ([ADDRESS_532535] Dose of 
GO) ..................................................................................................................41
6.2.5. Follow-up Period ........................................................................................42
6.3. Patient Withdrawal..................................................................................................42
7. ASSESSMENTS................................................................................................................. .44
7.1. Electrocardiogram Assessment ...............................................................................44
7.1.1. QT Interval Prolongation............................................................................447.1.2. Core Laboratory Manual Measurement for ECGs/QTc .............................45
7.2. Pharmacokinetics Assessment.................................................................................45
7.2.1. Pharmacokinetic Samples...........................................................................45
CCI
Gemtuzumab Ozogamicin (MYLOTARG ™)
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 57.3. Immunogenicity ......................................................................................................46
7.4. Safety Assessments .................................................................................................47
7.4.1. Veno-occlusive Disease Assessments and Sinusoidal Obstruction 
Syndrome .........................................................................................................47
7.5. Response Assessments ............................................................................................497.6. Survival .................................................................................................................. .50
7.7. Pregnanc y Testing ...................................................................................................50
7.9. Imaging Assessments ..............................................................................................51
8. ADVERSE EVENT REPORTING......................................................................................52
8.1. Requirements...........................................................................................................52
8.1.1. Additional Details on Recording Adverse Events on the CRF...................538.1.2. Eliciting Adverse Event Information..........................................................538.1.3. Withdrawal from the Study Due to Adverse Events (see also the 
Patient Withdrawal Section 6.3) ......................................................................53
8.1.4. Time Period for Collecting AE/SAE Information......................................54
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety...............................................[IP_ADDRESS]. Recording Non-serious AEs and SAEs on the CRF .................54
8.1.5. Causality Assessment .................................................................................558.1.6. Sponsor’s Reporting Requirements to Regulatory Authorities ..................[ADDRESS_532536] Findings .............................................................................568.2.3. Serious Adverse Events ..............................................................................568.2.4. Hospi[INVESTIGATOR_059]............................................................................................57
8.3. Severity Assessment................................................................................................588.4. Special Situations ....................................................................................................59
8.4.1. Protocol-Specified Serious Adverse Events ...............................................598.4.2. Potential Cases of Drug-Induced Liver Injury............................................608.4.3. Potential VOD/SOS Cases..........................................................................618.4.4. Exposure to the Investigational Product During Pregnancy or 
Breastfeeding, and Occupational Exposure .....................................................61CCI
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Exposure During Pregnancy ................................ ...................... 62
[IP_ADDRESS]. Exposure During Breastfeeding ................................ ................ 63
[IP_ADDRESS]. Occupational Exposure ................................ ............................. 63
8.4.5. Medication Error s .......................................................................................63
[IP_ADDRESS]. Medication Errors ................................ ................................ ......64
9. DATA ANALYSI S/STA TISTICAL  METHODS ................................ ............................... 64
9.1. Sample Size Determination ................................ ................................ ..................... 64
9.2. Analy sis Sets ................................ ................................ ................................ ........... 65
9.2.1. Full Analy sis Set ................................ ................................ ......................... 65
9.2.2. Safet y Anal ysis Set ................................ ................................ ..................... 65
9.2.3. QTc Anal ysis Set ................................ ................................ ........................ 65
9.2.4. PK Analy sis Set ................................ ................................ .......................... 65
9.2.5. PK/PD Analy sis Set ................................ ................................ .................... 65
9.3. Planned Anal yses................................ ................................ ................................ ....65
9.3.1. Analysis of Prima ry Endpoint ................................ ................................ ....65
9.3.2. Analy sis of Secondary  Endpoints ................................ ............................... 66
[IP_ADDRESS]. Safet y Anal ysis................................ ................................ .......... 66
[IP_ADDRESS]. Pharmacokinetic Analy sis................................ ......................... 67
[IP_ADDRESS]. Pharmacokinetic/Pharmacod ynamic (PK/PD) Anal ysis........... 67
[IP_ADDRESS]. QTc-Concentration Analy sis................................ ..................... 67
[IP_ADDRESS]. I mmunogenicity ................................ ................................ ........ 68
[IP_ADDRESS]. Efficacy  Anal yses................................ ................................ ......[ADDRESS_532537] KEEPI[INVESTIGATOR_1645] ................................ ............................. 69
11.1. Case Report Forms/Electronic Data Record ................................ ......................... [ADDRESS_532538]/Ethics Committee ................................ ...................... [ADDRESS_532539] of the Study ................................ ................................ ................ 71
12.3. Patient I nformation and Consent ................................ ................................ ........... 71
Gemtuzumab Ozogamicin (MYLOTARG ™)
B1761031
Protocol, [ADDRESS_532540] OF TABLES
Table 1. Schedule of Activities...........................................................................................12
Table 2. Schedule of Activities – ECG, Pharmacokinetics, Immunogenicity, 
Pharmacodynamics .................................16
Table 3. Dosage Modifications for Non hematologic and Hematologic Toxicities ...........31Table 4. EBMT Criteria for VOD/SOS Diagnosis .............................................................48Table 5. European Leukemia Net (ELN 2017) Recommendations
5...................................[ADDRESS_532541] of Drugs Known to Predispose to Torsades de Pointes ...............................84Appendix 5. Definition of Refractory and Relapsed AML (ELN 2017 
Recommendation)
5...............................................................................................85CCI
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 8PROTOCOL SUMMARY
Back ground and Rationale:
Gemtuzumab ozogamicin (GO, MYLOTARG) is an antibody -drug conjugate (ADC) 
composed of the cluster of differentiation 33 (CD33) -directed monoclonal antibody  
hP67.6 (recombinant humanized immunoglobulin [I g] G4, kappa antibody  produced by 
[CONTACT_421923]0 cells) that is covalently  linked to the cy totoxic agent 
N-acety l-gamma -calicheamicin dimethy lhydrazide (DMH), a semis ynthetic disulfide 
derivative of calicheamicin.  The antibody  portion binds specificall y to the CD33 antig en, a 
sialic acid -dependent adhesion protein found on the surface of m yeloid leukemic blasts and 
immature normal cells of my elomonocy tic lineage, but not on normal hematopoietic stem 
cells.
On 01 September 2017, the US Food and Drug Administration (FDA) ap proved GO 
(MYLOTARG) for the treatment of adult patients with newly  diagnosed CD33- positive 
acute m yeloid leukemia (AML) and for the treatment of adult or pediatric patients at least 
2years of age with relapsed/refractory  CD33 -positive AML .1  In adults with newly  
diagnosed CD33- positive AML , GO can be administered as part of a combination regimen 
(ie,fractionated dose of 3 mg/m2on Day s1, 4, and 7 combined with daunorubicin [DNR] 
and cy tarabine [Ara -C] during induction) or as a single agent (ie, 6 mg/m2on Day 1 and 
3mg/m2on Day 8 of induction).  In the setting of relapsed/refractory  CD33 -positive AML  in 
patients aged 2 years and older, GO is approved for use as a single agent only  using the 
fractionated dosing regimen (ie, 3 mg/m2on Days 1, 4, and 7) .1
During their review of the Biologics L icense Application (BL A), the FDA issued 
post-marketing requirements (PMRs) that requested additional assessment of the impa ct of 
the fractionated dosing regimen of GO on the risk of veno -occlusive disease or sinusoidal 
obstruction sy ndrome (VOD/SOS) in patients with previous or subsequent hematopoietic 
stem cell transplantation (HSCT), hemorrhage, unexpected serious risk of QT interval 
prolongation, and unexpected serious risk of anti -drug antibodies.  Additionally , no clinical 
pharmacokinetics (PK) data for GO, represented by  [CONTACT_421924]67.[ADDRESS_532542] been 
characterized following the fractionated dosing regimen.  The PK prof iles included in the 
BLA used for exposure -response modeling of the pi[INVESTIGATOR_9205] 3 trial, ie, Acute Leukemia 
French Association 0701 (ALFA-0701),2were simulated using population PK modeling 
based on 8 previous clinical trials.  Therefore, B1761031 has been planned to address these 
PMRs. 
On 22 February  2018, the Committee for Medicinal Products for Human Use (CHMP) 
adopted a positive opi[INVESTIGATOR_1649], and on 19 April 2018 the European Commission granted a 
marketing auth orization for My lotarg, indicated for combination therapy  with DNR and 
Ara-C for the treatment of patients age 15 years and above with previousl y untreated, 
denovo CD33- positive acute my eloid leukemia (AML), except acute promy elocy tic 
leukemia (APL).
Gemtuzumab Ozogamicin (MYLOTARG ™)
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 9The CHMP identified several recommendations in the ongoing development of GO, 
including the addition of  
6 pediatric 
patients into the FDA issued PMR study.  Therefore, this study will include 6 pediatric patients 12-17 years of age (eg, adolescents).  Patients within this defined age group are expected to have similar electrocardiogram (ECG)/PK findings, and are deemed acceptable for the schedule of assessments and blood draw requirements of this study.
Objectives and Endpoints:
Primary Objective: Primary Endpoint:
•To assess the effect of GO on the QTc interval. •Maximum change from baseline in 
corrected QT interval (QTc).
Secondary Objectives: Secondary Endpoints:
•To characterize the PK of single-agent GO following 
the fractionated regimen (ie, 3 mg/m² on Days 1, 4, and 7).
•To assess the safety of GO with fractionated dosing 
of 3 mg/m
2.
•To assess the immunogenicity of GO. 
•To assess response and overall survival.  •PK parameters: clearance and volume of 
distribution.
•Adverse events (AEs) and abnormal 
laboratory findings.
•Incidence of anti-drug antibody 
(ADA)/neutralizing antibodies (NAb). 
•Response: complete remission (CR) and 
complete remission with incomplete 
hematologic recovery (CRi) achieved after 
GO.
•Overall Survival. 
 
 
 
 
  
 
 
 
 
 
Study Design:
This is a single-arm, open-label, Phase [ADDRESS_532543] of GO on the QTc, 
pharmacokinetics, safety, and immunogenicity of GO as a single-agent monotherapy in adult and pediatric patients with relapsed or refractory CD33-positive AML.  Approximately 
50 adult (age ≥18 years) and 6 pediatric (12 years ≤age ≤17 years) patients who satisfy the 
study eligibility criteria will be enrolled.  Enrolled patients will receive the fractionated regimen of GO 3 mg/m
2up to [ADDRESS_532544] of GO 
on VOD/SOS in the context of previous and subsequent HSCT will also be assessed. CCI
CCI
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 10Treatment Plan
Patients enrolled in the study  will receive three doses of GO 3 mg/m2(up to one vial) as a 
2-hour intravenous infusion on Cy cle 1 Day s1, 4, and 7. A second cy cle of GO 3mg/m² (up 
to one vial) on Cy cle 2 Day s 1, 4, and 7 will be allowed at the investigator’s dis cretion for 
patients who meet the following criteria after C ycle 1: Bone marrow with a decrease of blast 
percentage to at least 25% or a decrease of pretreatment blast percentage by [CONTACT_2669] 50% ;
andBlood count with neutrophils 1,000/µL  and platelets 50,000/µL , except in patients 
with the bone marrow blasts 5%, the decrease in neutrophils and platelets thought to be due 
to the underlying leukemia (refer to Section 7.5).
After GO treatment, subsequent anticancer therapy  such as consolidation or conditioning 
regimen and/or HSCT could be considered at the investigator’s discretion.  A minimum 
interval of [ADDRESS_532545].
Assessments:
QTc In terval
Triplicate ECGs will be performed at screening, baseline (prior to dose on Day 1) and 
immediately  preceding serial PK draws on each day  of dosing.  A 12 -lead tracing will be 
used for all ECGs, including measurements of PR interval, QT interval, RR interval, a nd 
QRS complex.  All triplicate ECG tracings will be sent to an independent ECG core 
laboratory  for blinded manual interval measurements.3
Pharmacokinetics (PK)
Blood samples will be collected from all particip ating patients for PK anal ysis according to 
the PK schedule.  Samples will be collected prior to each dose and at time points around the 
maximum concentration (C max), ie, at the end of the 2 -hour infusion in order to characterize 
the QTc -concentration rela tionship. 
Safety
Safety  will be monitored per the protocol specified schedule.  Safety  assessments include 
adverse events (AEs) graded according to the National Cancer Institute Common 
Terminology  Criteria for Adverse Events ( NCI CTCAE , version 4.03), cli nical examination 
(including blood pressure and pulse), ECGs, and laboratory  tests (hematology , chemistry , 
coagulation and urinal ysis), including hemorrhage -related laboratory  data and 
coagulation -related assessments, such as complete blood counts and diff erential counts, 
prothrombin time (PT), activated partial thrombin time (aPTT), and fibrinogen. 
Any events of veno -occlusive disease (VOD) and sinusoidal obstruction syndrome (SOS) 
will be reported as serious adverse event (SAE) during the study  duration.   Details of the 
HSCT will be collected in order to assess the impact of the fractionated regimen of GO on 
the risk of VOD/SOS with previous or subsequent HSCT. 
Gemtuzumab Ozogamicin (MYLOTARG ™)
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 11Immunogenicity
Anti-drug antibody (ADA) samples will be collected as specified in the protocol.  Samples 
will be analyzed for ADAs using a tiered approach of screening, confirmation, and titer determination.
[ADDRESS_532546] positive for ADA will be further characterized to determine 
whether neutralizing antibodies (NAb) are present.
Efficacy
Efficacy evaluation anddetermination of remission status by [CONTACT_421925][INVESTIGATOR_1516] (and biopsy if applicable) will be conducted at the end of each cycle using European Leukemia Net (ELN 2017) recommendations (see Section 7.5 ).
5  Survival status 
for each patient will be collected for the study duration of 12 months. 
 
Statistical Methods:
The sample size is based on ensuring sufficient data to exclude a 20 milliseconds (msec)
mean increase 20 msec in the QT interval using the Fridericia heart rate correction (QTcF).  If the upper bounds of one-sided 95% confidence intervals of change from baseline in QT measurements using the Fridericia’s heart rate correction for each of the QTc sampling time points (on Day 4, at 0 hours, and Day 7, at 0, 2, 4, and 6 hours) are below [ADDRESS_532547]-baseline dose QTc interval will be considered to be “non-inferior” to the baseline.CCI
Gemtuzumab Ozogamicin (MYLOTARG ™)
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 12SCHEDULE OF ACTIVITIES
The Schedule of Activities table provides an overview of the protocol visits and procedures.  Refer to the STUDY PROCEDURES
(see Section 6 ) and ASSESSMENTS (see Section 7 ) sections of the protocol for detailed information on each procedure and 
assessment required for compliance with the protocol.  The investigator may schedule visits (unplanned visits) in addition to th ose 
listed on the Schedule of Activities table, in order to conduct evaluations or assessments required to protect the well-being o f the 
patient.
Table 1. Schedule of Activities
Screening Cycle 1 Cycle 2                               
(if administered)EOT Follow-up 
Period19
GO Treatment Post-GO Period GO Treatment Post-GO Period
Schedule Day1<28 days 
prior to 
enrollmentC1
D1C1
D4C1
D7C1
D10C1
D15C1
D21C2
D1C2
D4C2
D7C2
D10C2
D15C2
D21Every 12 weeks
Visit window (Days) ±1±1±1 ±1 ±1 ±1 ±2 ±7
Informed consent & 
assent3X
Immunophenotypi[INVESTIGATOR_007] (including CD33)
4X
 
ECG (in triplicate)6XX X X X X
Pharmacokinetic samples
7XXX X7X7X7X7X7X7X7X
Medical history8X
Body weight X X X X X X X
Vital signs/PE X X X X X X X
ECOG PS score9XX X
Imagingassessment
10X10X10X10CCI
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 13Table 1.Schedule of Activities
Screening Cycle 1 Cycle 2                                                       
(if adm inistered )EOT Follow -up 
Period19
GO Treatm ent Post-GO Period GO Treatm ent Post-GO Period
Schedule Day1<28 days 
prior to 
enrollmentC1
D1C1
D4C1
D7C1
D10C1
D15C1
D21C2
D1C2
D4C2
D7C2
D10C2
D15C2
D21Every 12 weeks
Visit window (Days) 1 1 1 1 1 1 2 7
Safety Laboratory11
CBC and differential 
counts12X X X X X X12X X X X X12X
Chemistry X X X X X X X X X X X X X X X17
Urinalysis X X X
Coagulation
(PT, aPTT, 
fibrinogen)X X X X X X X X X X X
Pregnancy t est X13X20
HIV, Hepatitis B, 
and Hepatitis C 
evaluation14X
Pre-medication X X X X X X
BMexamination  
and disease 
assessments15X15X15
Serious and non -
serio us adverse event 
monitoring16X X X X X X X X X X X X X X X17
Concomitant 
medications and 
treatment18X X X X X X X X X X X X X X X
Survival follow -up19X21
Abbreviations: aPTT = activated partial thromboplastin time; BM =bone marrow; C = C ycle; CAT = computed axial to mography; CBC = complete blood 
counts; D = D ay;ECG = electrocardiogram; ECOG PS= Eastern Cooperative Oncology Group performance status; EOT = end of treatment; GO =gemtuzumab 
ozogamicin; HIV = human immunodeficiency virus; MRI = magnetic resonance imagi ng; PE = physi cal exam ination ; PT = prothrombin time
Gemtuzumab Ozogamicin (MYLOTARG ™)
B1761031
Protocol, [ADDRESS_532548] enrollment day (Day 1) is the day when patient identifier is assigned  with the first GO dose.  The 
EOT is defined as [ADDRESS_532549] dose of GO or start of subsequent anticancer therapy, eg, consolidation and/or conditio ning regimens.
2. The second cycle will be allowed at the investigator’s discretion for patients who meet the following criteria after Cycle 1( see also Table 3 describing 
hematologic toxicities): Bone marrow with a decrease of blast percentage to at least 25% or a decrease of pretreatment blast perc entage by [CONTACT_2669] 50%; and 
Blood count with neutrophils ≥1,000/μL and platelets ≥50,000/μL, except in patients with the bone marrow blasts ≥5%, the decrease in neutrophils and 
platelets thought to be due to the underlying leukemia.  Patients who do not meet these response criteria after the first cycle of GO will not be allowed to 
receive a 2ndcycle see Section 7.5 ). Cycle [ADDRESS_532550] dose of GO (ie, Cycle 1 Day 7).
3. Informed Consent and assent for those patients under age 18 (or as specified per local policy/laws).  Must be obtained prior t o undergoing any study 
procedure.
4. CD33 immunophenotypi[INVESTIGATOR_421907] (BM) or of circulating blasts in peripheral blood specimen by [CONTACT_421926].  
Surface CD33 expression should be measured by [CONTACT_4133] (flow-activated cell sorting, FACS); immunohistochemistry (IHC) ana lysis is allowed in 
patients with (1) dry tap; or (2) if BM specimen is inadequate and/or with insufficient circulating blasts for FACS.  
 
 
 
6. ECGs will be in triplicate (3 consecutive ECGs approximately 2 minutes apart).  All ECGs will be sent to an ECG core laboratory  vendor.  ECG at screening 
will be used to determine patient eligibility.  Ideally, the patient will be supi[INVESTIGATOR_421908] a semi recumbent position fo r the entire infusion and for both 
pre- and post- infusion ECGs.  To minimize artifact, the patient should not change position between the pre- and post-infusion ECGs .  Additional ECGs may 
be done if clinically required.  See Table 2 for additional collection time points.
7. Pharmacokinetic samples: See Table 2 for additional time points.
8. Medical History: To be collected within [ADDRESS_532551] 
and outcomes, and cytogenetics.  Also, review study eligibility.
9. ECOG PS: Assessment is not required on Day [ADDRESS_532552] imaging assessment (eg, CAT or MRI) of all known disease sites.11. Days 1, 4, and 7 laboratory samples should be collected prior to dosing.  12. Three times a week after GO dosing until determination of remission status (see Section 7.5 ); subsequently CBC and differential counts will be collected 
once weekly until EOT (or until start of Cycle 2 (if administered) or start of subsequent anticancer therapy).
13. Pregnancy test: Required in less than 7 days prior to Day 1.14. Evaluations of HIV and hepatitis B serological tests and hepatitis C tests (see Section 6.1 ).
15. Efficacy evaluation anddetermination of remission status by [CONTACT_421927][INVESTIGATOR_1516] (and biopsy if applicable) afte r recovery of blood counts is 
observed and/or at a maximum of [ADDRESS_532553] dose of GO treatment.
16. Adverse Event (AE) Assessments: Adverse events should be documented and recorded at each visit using NCI CTCAE version 4.[ADDRESS_532554] dose of GO or start of subsequent anticancer therapy, (eg, consolidation or conditioning regimen), whichever occurs first.   Patients must be followed for 
AEs according to Section 8 .  Sites should report related SAEs including VOD/SOS as warranted.  Any occurrence of VOD/SOS is to be reported as SAE to 
[COMPANY_007] Safety and recorded in the case report form (CRFsee Section 7.4.1 ).C
CICCI
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 1517.Occurrence of VOD/SOS will be monitored for the study duration of 12 months for each patient (see Section 7.4.1 ). During Follow -up period, blood 
chemistry sampling should be collected only in case of occurrence of VOD/SOS.
18.Concomitant Medications/Treatments: Concomitant medications and treatments will be recorded from [ADDRESS_532555] dose of study treatment or s tarting subsequent anticancer therapy (eg, consolidation or conditioning regimen).  During the follow -up 
period concomitant medications only related to follow -up therapy/HSCT and the management of VOD/SOS are to be collected ( seeSection 7.4.1 ).  Also, the 
patient will be informed of the need to use 2 highly effective methods of contraception consistently and correctly and document the conversation, and the 
patient’s affirmation, in the patient’ s chart (see Section 4.3.1 ). 
19.Post BM assessment and determination of response: Consolidation as well as the decision of subsequent HSCT will be at physici an’s discretion.  The study 
duration for each patient is [ADDRESS_532556] subsequent 
to GO regimen will undergo relevant laboratory tests for safety monitoring per institutional standards for su spected or diagnosed VOD/SOS. 
20.Pregnancy test (see Section 7.7).
21.For any patients who may not be able to visit the study site at the protocol designated time, telephone contact [CONTACT_421928] -up 
plus collecting cause(s) of death.
Gemtuzumab Ozogamicin (MYLOTARG ™)
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 16Table 2. Schedule of Activities – ECG, Pharmacokinetics, Immunogenicity  
Assessments
Cycle 1 Cycle 2 (if administered) EOTl
(±±2 
days)Follow-up 
Period
D1 D4 D7 D10
(±1 
day)D15
(±1 
day)D21
(±1 
day)D1 D7 D15
(±1 
day)D21
(±1 
day)
Time (hours) relative to the 
start of the GO infusion0 1 2 4 6 24 0 2 0 2 4 6 NA NA NA 0 2 0 2 6 NA NA NA NA
Blood sample for PKaXbXdXcXdXdXjXbXcXbXcXdXdXeXeXeXbXcXbXcXdXeXeXe
 
 
Blood sample for ADA/NAbcXbXeXeXeXeXeXm
Triplicate 12-lead ECGfXXXX XXXXXX XXXXX
 
 
 
ADA = anti-drug antibody; D = Day; ECG = electrocardiogram; EOT = end of treatment; GO = gemtuzumab ozogamicin; NA = not applicable;NAb = neutralizing antibody; PD = pharmacodynamics; PK = pharmacokinetics 
a. PK samples collected during infusion should be taken from the arm OPPOSITE to the IV infusion site. 
PK sample should ALWAYS be collected AFTER ECG.If the dosing day is delayed, the PK and PD samples must be collected on the same day as dosing.
PK collections on Day [ADDRESS_532557]-dose samples are to be drawn right before the infusion ends (maximum window of ±10 minutes allowed). 
d. These post-dose samples to be drawn within ±10 minutes of the designated time.
e. Samples on Days 10, 15, 21, and EOT visit may be collected at any time during the visit.
f. Triplicate 12-lead ECG: At each time-point, three consecutive 12-lead ECGs will be performed approximately [ADDRESS_532558] intervals automatically.  ECG interval readings by [CONTACT_4635]’s algorithm will be read  and interpreted at the 
investigational site for eligibility determination.  Additional ECGs will be performed as clinically indicated for patient safe ty monitoring and documentation 
stored in the source documents.  ECG measurements will include PR interval, QT interval, RR interval and QRS complex.  
 CCI
C
CI
CCI
CCI
Gemtuzumab Ozogamicin (MYLOTARG ™)
B1761031
Protocol, [ADDRESS_532559] dose of GO.
m. The follow-up for patients who are ADA positive at the EOT visit ([ADDRESS_532560] dose) consists of visits approximately e very [ADDRESS_532561].C
CCCI
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 181.INTRODUCTION
1.1.Mechanism of Action/Indication
The CD33 (cluster of differentiation) antigen is a cell surfac e protein expressed on the 
external surface of normal and leukemic myeloid cells, and leukemic blasts in more than 
80-90% of patients with acute m yeloid leukemia (AML).  The antigen is not expressed on the 
pluripotent stem cells, normal precursor hematopoi etic cells.6
Gemtuzumab ozogamicin (GO; MYLOTARG ) is an antibody -drug conjugate (ADC) 
composed of the CD33 -directed monoclonal antibody  (recombinant humanized 
immunoglobulin [I g]G4, kappa antibody  produced by [CONTACT_421923]0 cells) 
that is covalently  linked to the cy totoxic agent N -acetyl gamma calicheamicin 
dimethy lhydrazide (DMH), a semis ynthetic disulfide derivative of calicheamicin.  The 
antibody  portion binds specificall y to the CD33 antigen , a sialic acid -dependent adhesion 
protein found on the surface of m yeloid leukemic blasts and immature normal cells of 
myelomonocy tic lineage, but not on normal hematopoietic stem cells.  After binding to the 
CD33 antigen, GO is internalized within the le ukemic cell, thus delivering the calicheamicin 
derivative.7  Activation of N -acetyl gamma calicheamicin DMH induces double -strand 
deoxy ribonucleic acid (DNA) breaks, subsequently  inducing cell cy cle arrest and a poptotic 
cell death.8  GO, the onl y approved AML therap y that targets CD33 antigen, is indicated for 
the treatment of newl y-diagnosed CD33- positive acute my eloid leukemia (AML) in adults, 
and relapsed or refractory  CD33 -positive AML in adults and in pediatric patients 2 years and 
older.1
1.2.Background and Rationale
1.2.1. Incidence and Treatment of Acute Myeloid Leukemia (AML)
Acute m yeloid leukemia (AML) is the most common typ e of acute leukemia in adults and 
accounts for ~80% of all cases of acute leukemia.  Each year there are approximately  
260,000 new cases of AML  worldwide with incidence 4.2 per 100,000; of these about 
21,380 cases are estimated in US.9  The average age of a patient with AML is about 68 years 
and it is relatively  uncommon before the age of 45.  I ncidence increases with age and peaks 
in adults 65 years of age or older; slightly more than half of all patients are [ADDRESS_532562] of care induction chemotherapi[INVESTIGATOR_421909], or hy pomethy lating agents (eg, decitabine and azacitidine) can 
induce complete remissions in 5 -70% of patients; however, remissions are not durable and 
disease relapse occurs in up to 60% of patients.[ADDRESS_532563] a particularly poor 
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, [ADDRESS_532564] been used for 
salvage chemotherap y and remission rates from 20 –70% have been described.  However, the 
period of remission ty pi[INVESTIGATOR_421910] y 4-6months. 
1.2.2. Gemtuzumab Ozogamicin for Treatment of Acute Myeloid Leukemia
[IP_ADDRESS]. Regulatory History
Gemtuzumab ozogamicin originally  received accelerated approval with dose of 
9mg/m² x 2(14days apart) gi ven as a single -agent treatment for patients with CD33- positive 
AML  in first relapse who are 60 years of age or older and who are not considered candidates 
for cy totoxic chemotherapy  in the [LOCATION_002] (US) on 17 May  2000 and as a monotherapy  
for the tre atment of patients with relapsed or refractory CD33 -positive AML in Japan in 
2005.  A Phase 3 study  (Southwest Oncology  Group [SWOG] S0106) evaluating GO in 
combination with chemotherap y in patients with previously  untreated de novo AML  was 
subsequently  conducted as a post -market requirement (PMR) from 2004 to 2009 to confirm 
the clinical benefit of GO in order to convert the accelerated approval to full approval.  
S0106 was a randomized trial comparing treatment with DNR and Ara -C with or without GO 
6mg/m2for treatment of patients <60 years old with newly -diagnosed AML.  The primary  
endpoint was complete remission (CR) rate post induction and disease -free survival (DFS) 
post consolidation.  There were 637 patients randomized.  The study  showed no 
improvem ent in CR, DFS or overall survival (OS) with the addition of GO.  I n addition, there 
was a higher rate of fatal induction toxicities in the GO arm (5.8% versus 1.3%).  FDA 
concluded that clinical benefit was not confirmed and that there was a potential saf ety issue 
due to the increase in early  deaths.  In addition, GO was associated with hepatic 
veno -occlusive disease (VOD), which has substantial morbidity  and mortality .  Therefore, 
[COMPANY_007] voluntarily  withdrew M ylotarg from the US market in October 2010.  N evertheless, 
GO continued to be marketed for the treatment of patients with relapsed or refractory 
CD33- positive AML  in Japan, hematologists requested compassionate -use GO for their 
AML  patients, and investigators continued to evaluate GO in patients with AML .
On 01 September 2017 the US FDA approved My lotarg for adults with newly  diagnosed 
CD33- positive AML , and for adults and children 2 years and older with relapsed or 
refractory  CD33- positive AML .  Study  ALFA -0701 supported use of GO in combination 
with chemotherap y in newly diagnosed AML, EORTC (European Organisation for Research 
and Treatment of Cancer) - GIMEMA (Gruppo Italiano Malattie Ematologiche dell' Adulto) 
AML -19 Study  supported use of single -agent GO in newly  diagnosed AML,23and Study  
Mylo[LOCATION_009] -1 supported use of single -agent GO in relapsed or refractory  AML .  The 
approved dosage is as follows:1
Combination regimen in newly -diagnosed AML: Induction with 3 mg/m2on Day s 1, 
4, and 7 in combination with DNR and Ara -C, followed by  [CONTACT_421929] 
3mg/m2on Day 1 in combination with DNR and Ara -C.
Single -agent regimen in newly -diagnosed AML: Induction with 6 mg/m2on Day 1 
and 3 mg/m2on Day 8, followed by  [CONTACT_421930] a dose of 2 mg/m2every  4weeks for 8 doses. 
Gemtuzumab Ozogamicin (MYLOTARG ™)
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 20•Single-agent regimen in relapsed or refractory AML: 3 mg/m2on Days 1, 4, and 7. 
On 22 February 2018, the Committee for Medicinal Products for Human Use (CHMP) 
adopted a positive opi[INVESTIGATOR_1649], and on 19 April 2018, The European Commission (EC) granted a marketing authorisation approval for Mylotarg, indicated for combination therapy with DNR and Ara-C for the treatment of patients age 15 years and above with previously untreated, de novo CD33-positive acute myeloid leukemia (AML), except acute promyelocytic 
leukemia (APL).
[IP_ADDRESS]. Fractionated Dosing of GO
Based on in vitro studies, which showed rapid re-expression of CD33 antigenic sites on the 
cell surface of blasts cells after exposure to GO, it was hypothesized that fractionated doses of GO may be efficacious and better tolerated.
[ADDRESS_532565] 90% of CD33 saturation is required for efficient killing of AML blasts .
12The initial dose-escalation 
Study 101 (N=40) in relapsed AML evaluated CD33 site saturation of GO over a dose range of 0.25 to 9 mg/m
2.  Based on these results, a dose of 3 mg/m2is estimated to produce 
90% to 95% saturation of CD33.13  Based on exposure-response modeling, lower fractionated 
dosing of GO was predicted to retain efficacy and improve safety.  This is particularly important in patients who undergo hematopoietic stem cell transplantation (HSCT), a significant risk factor of VOD/SOS.
The safety and efficacy of the fractionated dose GO monotherapy regimen of 3 mg/m
2on 
Days 1, 4, and 7, in patients with CD33-positive AML in first relapse has been demonstrated in a Phase 2 study (Mylo[LOCATION_009]-1).
14
[IP_ADDRESS].  Pharmacokinetics and Dosage
GO was originally approved for use in patients with CD33-positive relapsed AML.  Three 
registrational Phase 2 studies (0903B1-201, 0903B1-202, 0903B1-203) were conducted.15  
The approved regimen was 2 doses of GO at 9 mg/m2, administered at least 14 days apart.  
The 14-day interval between doses was selected on the basis of near total clearance of the antibody portion of GO, hP67.6, within this time period.  Based on the non-compartmental analysis (NCA) following a 9 mg/m
2dose on Days [ADDRESS_532566] dose and 90 hours after the second dose.
Since no clinical pharmacokinetic (PK) data are available for the fractionated dosing regimen 
for GO (3 mg/m2administered on Days 1, 4, and 7), PK profiles for this regimen were 
simulated, using the PK model developed based on prior clinical studies, in patients with relapsed or refractory AML or de novo AML.  The model predicted that, while the total dose of the fractionated dosing regimen is half of that of the original dosing regimen (9 versus 18 mg/m
2), total area under curve (AUC) of hP67.6 over the course of treatment is 25%, and 
maximum concentration (C max) is 24% of the original dosing regimen.  Since the C maxhas 
been associated with the risk of certain AEs (eg, VOD/SOS, bilirubin elevation, aspartate aminotransferase [AST] elevation), the fractionated regimen is expected to have improved safety profile than the previously used regimen.
13CCI
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Clinical Data for GO in Patients with AML in First Relapse
Studies 201, 202, and [ADDRESS_532567] re lapse that supported the original accelerated approval of M ylotarg by  [CONTACT_167732] 2000 .15  These studies shared a similar design and used an identical GO dosing regimen 
of 9mg/m2on Day s 1 and 15.  The prim ary objective of these studies was to assess the 
efficacy  (based on the number of patients achieving CR or complete remission with 
incomplete platelet recovery  [CRp]) and safety  of GO monotherapy .  A pooled anal ysis of 
these 3 pi[INVESTIGATOR_9205] 2 studies (N=277) reported an objective response rate of 35% (based on 
International Working Group [I WG] criteria).16  The evidence from these studies indicated 
that patients receiving GO had a high incidence of my elosuppressi on, manifested by  [CONTACT_421931], and over time, hepatic VOD (SOS) 
emerged. 
A Phase 2 study  (My lo[LOCATION_009] -1) used the fractionated regimen of single -agent GO (3 mg/m2
on Day s 1, 4, and 7), followed b y consolidation with high -dose cytarabine in patients with 
AML  in first relapse.  Of 57 patients who received GO, 15 patients (26%) achieved CR and 
four patients (7%) achieved CRp.  I n the 19 patients who achieved a response in the
Mylo[LOCATION_009] -1 study , the median times to recovery of neutrophil count to 500/mm3and of 
platelet count to 50,000/mm3were 23 and 20 days, respectivel y, approximately half the 
median time to recovery  observed in Studies 201/202/203 (40.5 days and 51 days, 
respectively).  Grade 3 treatment emergen t adverse events (TEAEs) reported in >1% patients 
in the My lo[LOCATION_009] -1 study  included sepsis (31.5%), fever (15.8%), rash (10.5%), 
pneumonia (7.0%), bleeding (7.0%), mucositis (3.5%), and diarrhea, headaches, tach ycardia, 
and edema (1.8% each).  Grade 3or4 liver toxicity was not reported; also, there were no 
reports of VOD/SOS, including in [ADDRESS_532568] subsequent to GO 
treatment.14  
Additional information for this compound may  be found in the single reference safet y 
document (SRSD), which for this study  is the investigator brochure (IB).
[IP_ADDRESS]. Study Rationale 
Results from the studies evaluating treatment with GO in patients with CD33 -positive AML  
in first relapse, described in Section [IP_ADDRESS], provide evidence that fractionated regimen of 
GO has enhanced safet y profile than the original dosing regimen, without hampering the 
efficacy . 
The effect of GO on the QT interval has not been evalu ated clinically  because the regulatory  
guidelines when the original studies (201, 202, and 203) were conducted did not require 
quantitative QT data to be collected.  However, tests evaluating the effect o f N-acetyl gamma 
calicheamicin DMH on the human ethe r-a-go-go- related gene (hERG) potassium channel at 
concentrations up to 6.77 uM resulted in <1% inhibition of the hERG current amplitude and 
there were no effects of GO on ECG parameters in dogs at an y dose (range 4 to 40 mg/m2) or 
in monkey s in the 6- week repeat -dose studies.  Additionally , no PK data are available for the 
fractionated dosing regimen (3 mg/m2on Day s 1, 4, and 7) of GO.  Therefore, FDA has 
requested a PMR study  to characterize the effect of the fractionated dosing regimen of GO as 
Gemtuzumab Ozogamicin (MYLOTARG ™)
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 22a single-agent treatment in patients with relapsed or refractory CD33-positive AML on QT 
interval, PK, and safety. In addition, the CHMP identified several recommendations in the ongoing development of GO, including  
 
 inclusion of 6 pediatric patients into the FDA issued PMR study.  The 6 pediatric 
patients in this study will be between 12 and 17 years of age (eg, adolescents), a defined group of pediatric patients expected to have similar ECG/PK findings and for whom the schedule of assessments and blood draw requirements would be acceptable in order not to exceed 3% of total blood volume within [ADDRESS_532569] of GO on the QT interval, as well as to enhance the understanding of GO following the fractionated regimen in patients with relapsed or refractory AML.  
Six (6) pediatric patients (12 years ≤age ≤17 year) will be included based on agreement with 
CHMP.  This study includes the collection of hemorrhage-related laboratory data and 
coagulation-related assessments, such as complete blood counts (CBC) and differential counts, prothrombin time (PT), activated partial thromboplastin time (aPTT), and fibrinogen.  The impact of GO on VOD/SOS in the context of previous and subsequent HSCT, and anti-drug antibody (ADA) formation will also be assessed.   
  
 
 
 
 
 
 
 
 
 
 
 
 CCI
CCI
CCI
CCI
Gemtuzumab Ozogamicin (MYLOTARG ™)
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 232. STUDY OBJECTIVES AND ENDPOINTS
Primary Objective: Primary Endpoint:
•To assess the effect of GO on the QTc interval. •Maximum change from baseline in 
corrected QT interval (QTc).
Secondary Objectives: Secondary Endpoints:
•To characterize the PK of single-agent GO following 
the fractionated regimen (ie, 3 mg/m² on Days 1, 4, and 7).
•To assess the safety of GO with fractionated dosing 
of 3 mg/m
2.
•To assess the immunogenicity of GO. 
•To assess response and overall survival.  •PK parameters: clearance and volume of 
distribution.
•Adverse events (AEs) and abnormal 
laboratory findings.
•Incidence of anti-drug antibody 
(ADA)/neutralizing antibodies (NAb). 
•Response: complete remission (CR) and 
complete remission with incomplete 
hematologic recovery (CRi) achieved after 
GO.
•Overall Survival. 
 
 
 
 
  
 
 
 
 
 
3. STUDY DESIGN
This is a single-arm, open-label, Phase [ADDRESS_532570] of GO on the QT, 
pharmacokinetics, safety, and immunogenicity of GO as a single-agent monotherapy in adultand pediatric patients with relapsed or refractory CD33-positive AML.  Approximately 
50 adult patients (age ≥18 years) and 6 pediatric (12 years ≤age ≤17 years) patients who 
satisfy the study eligibility criteria will be enrolled and treated with the fractionated regimen of GO 3 mg/m
2on Days 1, 4, and 7 (up to 2 cycles).  Triplicate ECGs will be performed at 
screening, baseline (prior to dose on Day 1) and right before serial PK draws on each day of dosing.  All triplicate ECG tracings will be sent to an independent ECG core laboratory for blinded manual interval measurements. The active safety monitoring duration will be up to [ADDRESS_532571] dose of GO or starting of subsequent anticancer therapy, including consolidation and/or conditioning regimens.  This study includes the collection of hemorrhage-related laboratory data and coagulation-related assessments, such as CBC and differential counts, PT, aPTT, and fibrinogen.  Any event of VOD/SOS will continue to be reported as SAE during the entire study duration. CCI
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 24After receiving the stud y treatment (C ycle 1 and Cycle 2, if administered), blood cell and 
differential counts will be examined 3 times a week after GO dosing until having 
determination of remission status (see Section 7.5 ); subsequently  CBC and differential counts 
will be collected once weekly  until [ADDRESS_532572] dose of GO or until start of 
subsequent anticancer therap y, eg, consolidation or conditioning regimen.  Eff icacy  
evaluation and final determination of remission status by  [CONTACT_421927][INVESTIGATOR_1516] 
(and biopsy  if applicable) will be conducted after recovery  of blood counts is observed or at a 
maximum of [ADDRESS_532573] dose of GO treatment (EOT).  Study  duration for each 
patient is a total of 12 months from enrollment, survival data will be collected for the study  
duration of 12 months. 
Treatment Plan
Patients enrolled in the study  will be receive three doses of GO 3 mg/m2(up to one vial) as a 
2-hour intravenous infusion on Cycle 1 Days1, 4, and 7.  A second cy cle 3mg/m² (up to one 
vial) on Cy cle 2 Day s 1, 4, and 7 will be allowed at the investigator’s discretion for patients 
who meet the following criteria after C ycle 1: Bone marrow with a decre ase of blast 
percentage to at least 25% or a decrease of pretreatment blast percentage by [CONTACT_2669] 50% ;
andBlood count with neutrophils 1,000/µL  and platelets 50,000/µL , except in patients 
with the bone marrow blasts 5%, the decrease in neutrophils and platelets thought to be due 
to the underly ing leukemia ( seeSection 7.5).
After GO treatment, subsequent anticancer therapy such as consolidation or conditioning 
regimen and/or HSCT could be considered at the investigator’s discretion.  A minimum 
interval of [ADDRESS_532574]. 
Figure 1. B1761031 Study Schematic
Confirmed 
refractory or 
relapsed CD33 -
positive AML 
Age 12years 
ECOG PS [ADDRESS_532575] 
allow ed (2 months 
prior to enrollment)Treatm ent
Monotherapy with GO 
2-hour intravenous ( IV)
infusion of 3 mg/m2(up to 
one vial) on Days 1, 4, and 7 
(1-2 cycles) 
Assessments: 
QTc, PK, Safety, 
immunogenicity, and 
EfficacyAfter GO Treat ment 
Subsequent anticancer 
therapy at the discretion 
of the investigator 
(eg,consolidation and/or 
HSCT)
HSCT allowed ([ADDRESS_532576])Pre-
medication
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, [ADDRESS_532577] patients for whom participation in the study  is 
considered appropriate.  All relevant medical and nonmedical conditions should be taken int o 
consideration when deciding whether a particular patient is suitable for this protocol. 
Patient eligibility  should be reviewed and documented by  [CONTACT_4653]’s study team before patients are included in the study . 
4.1.Inclusion Criteria
Patients must meet all of the following inclusion criteria to be eligible for enrollment into the 
study :
1.Refractory  or relapsed (ie, bone marrow blasts 5%) CD33- positive AML.
2.Age 12years. 
3.Eastern Cooperative Oncology  Group (ECOG) Performance Status 0 to 2.
4. Initial peripheral white blood cells (WBC) counts <30,000/ L; patients with a higher 
WBC count should undergo cy toreduction.
5.Adequate renal/hepatic functions, ie: 
Serum creatinine 1.5 x upper limit of normal (ULN) or an y serum creatinine 
level associated with a measured or calculated creatinine clearance of 
40mL/min;
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 
<2.5×ULN; total bilirubin <2×ULN.
6.Negative serum or urine pregnancy  (human chorionic gonadotropin [hCG]) t est 
within 1 week before treatment for women of child bearing potential.
7.Evidence of a personally signed and dated informed consent document and obtaining 
proper pediatric assent in addition to consent according to local regulations (by  [CONTACT_421932] l egally  acceptable representative [eg, parents] in the pediatric patients) 
indicating that the patient [or a legally acceptable representative/parent(s)/legal 
guardian] has been informed of all pertinent aspects of the study .
8.Willing and able to comply  with scheduled visits, treatment plan, laboratory tests, and 
other study  procedures.
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, [ADDRESS_532578] 1 of the following 
criteria:
Achieved postmenopausal status, defined as follows: cessation of regular menses 
for at least 12 consecutive months with no alternative pathological or 
physiological cause; status may  be confirmed with a serum follicle- stimulating 
hormone (FSH) level confirming the postmenopausal state;
Have undergone a documented hy sterectomy and/or bi lateral oophorectomy ;
Have medically  confirmed ovarian failure. 
All other female patients (including female patients with tubal ligations) are considered to be 
of childbearing potential. 
4.2. Exclusion Criteria
Patients with any  of the following characteristics/conditions will not be included in the study :
1.Patients with prior treatment with GO.
2.Patients with prior history  of VOD/SOS.
3.Prior HSCT is not allowed, if it was conducted within 2 months prior to study  
enrollment.
4.Patients with known active central ner vous s ystem (CNS) leukemia.
5. Uncontrolled or active infectious status.
6.Any of the following within the 3 months prior to starting study treatment: 
myocardial infarction, severe/unstable angina, coronary /peripheral artery  by[CONTACT_4660], congestive heart failu re, or cerebrovascular accident including transient 
ischemic attack, or sy mptomatic pulmonary  embolism.
7.Uncontrolled cardiac d ysrhythmias of NCI CTCAE Grade 2, uncontrolled atrial 
fibrillation of any  grade.
8.Sero-positivity  to human immunodeficieny  virus (H IV).
9.Active hepatitis B or hepatitis C infection (see Appendix 2).
10.Chemotherap y, radiotherapy, or other anti -cancer therap y (except h ydrox yurea as 
cytoreduction) within 2 weeks prior to enrollment in the study .
11.Major surgery  within 4 weeks prior to enrollment.
12.Diagnosis of an y other malignancy within 3 years prior to enrollment, except for 
adequatel y treated basal cell or squamous cell skin cancer, or carcinoma in situ of the 
cervix.
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 2713.QTc interval >470 milliseconds (msec) using the Fridericia (QTcF) (based on the 
mean value of the triplicate electrocardiograms [ECGs]), family  or personal history  of 
long or short QT sy ndrome, Brugada s yndrome or known history of QTc 
prolongation, or Torsade de Pointes (TdP).
14.The use of medications known to predispose to Torsades de Pointes within 2 weeks 
prior to enrollment (see Appendix 4).
15.History  of allergic reactions attributed to compounds of similar chemical or biologic 
composition to GO.
16.Investigator site staff me mbers directl y involved in the conduct of the study and their 
family  members, site staff members otherwise supervised by  [CONTACT_093], or 
patients who are [COMPANY_007] employ ees, including their family  members, directly  involved 
in the conduct of the study .
17. Participation in other studies involving investigational drug(s) within 2 weeks prior to 
study  entry  and/or during study  participation.
18.Other acute or chronic medical or ps ychiatric condition including recent (within the 
past y ear) or active suicidal ideat ion or behavior or laboratory  abnormality  that may  
increase the risk associated with study  participation or investigational product 
administration or may  interfere with the interpretation of study  results and, in the 
judgment of the investigator, would mak e the patient inappropriate for entry into this 
study .
19. Pregnant female patients; breastfeeding female patients; fertile male patients and 
female patients of childbearing potential who are unwilling or unable to use [ADDRESS_532579]. 
4.3.Lifestyle Requirements
4.3.1. Contraception
In this stud y, fertile male patients and female patients who are of childbearing potential as 
applicable to the study will receive GO, which has been associated with demonstrated 
teratogenicit y/fetotoxicity .  Patients who are, in the opi[INVESTIGATOR_871], sexually  
active and at risk for pregnancy  with their partner(s) must agree to use [ADDRESS_532580] dose 
of GO in male patients with female partners of re productive potential.  The investigator or his 
or her designee, in consultation with the patient, will confirm that the patient has selected 
2 appropriate methods of contraception for the individual patient and his/her partner(s) from 
the list of permitted contraception methods (see below) and will confirm that the patient has 
been instructed in their consistent and correct use.  At time points indicated in the Schedule 
of Activities, the investigator or designee will inform the pat ient of the need to use 2 highly  
effective methods of contraception consistentl y and correctly and document the conversation, 
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 28and the patient’s affirmation, in the patient’s chart.  In addition, the investigator or designee 
will instruct the patient to cal l immediately  if 1 or both of the selected contraception methods 
is discontinued or if pregnancy  is known or suspected in the patient or partner. 
Highly  effective methods of contraception are those that, alone or in combination, result in a 
failure rate o f less than 1% per year when used consistently  and correctly  (ie, perfect use) and 
include the following:
Established use of hormonal methods of contraception associated with inhibition of 
ovulation (eg, oral, inserted, injected, implanted, transdermal), p rovided the patient or 
male patient’s female partner plans to remain on the same treatment throughout the 
entire study  and has been using that hormonal contraceptive for an adequate period of 
time to ensure effectiveness.  
Correctly placed copper -containing intrauterine device (IUD).
Male condom or female condom used WI TH a separate spermicide product (ie, foam, 
gel, film, cream, or suppository ).  For countries where spermicide is not available or 
condom plus spermicide is not accepted as highly effective contraception, this option 
is not appropriate.
Male sterilization with absence of sperm in the postvasectomy  ejaculate. 
Bilateral tubal ligation/bilateral salpi[INVESTIGATOR_8820] y or bilateral tubal occlusive procedure 
(provided that occlusion has been confirmed in accordance with the device’s label).
All sexually  active male subjects must agree to prevent potential transfer to and 
exposure of partner(s) to drug through ejaculate by  [CONTACT_2329] a condom consistently  and 
correctly , beginning with the first dose of investiga tional product and continuing for 
[ADDRESS_532581] dose of GO. 
4.4. Sponsor’s Qualified Medical Personnel
The contact [CONTACT_1133]'s appropriately qualified medical personnel for the 
study  is documented in the study  contact [CONTACT_421933]. 
To facilitate access to appropriatel y qualified medical personnel on stud y-related medical 
questions or problems, patients are provided with a contact [CONTACT_1137].  The contact [CONTACT_4662], 
at a minimum, protocol and investigational product identifiers, patient study numbers, 
contact [CONTACT_22850], and contact [CONTACT_4664] a contact [CONTACT_74072] a medical 
question or problem originating from another healthcare professional not involved in the 
patient’s participation in the study .  The contact [CONTACT_421934]; however, it should be used only  
in the event that the established communication pathway s between the investigator site and 
the study  team are not available.  It is therefore intended to augment, but not replace, the 
established communication pathway s between the investigator site and the study  team for 
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, [ADDRESS_532582] 
number is not intended for use b y the patient directly, and if a patient calls that number, he or 
she will be directed back to the investigator site.
5.STUDY TREATME NT
For the purposes of this study , and per International Conference on Harmonisation (I CH) 
guidelines, investigational product is defined as a pharmaceutical form of an active 
ingredient or placebo being tested or used as a reference/comparator in a clini cal trial, 
including a product with a marketing authorization when used or assembled (formulated or 
packaged) in a way  different from the approved form, or when used for an unapproved 
indication, or when used to gain further information about an approved u se (ICH E6 1.33). 
For this study , the investigational product is gemtuzumab ozogamicin (GO).
5.1.Allocation to Treatment
Once the patient has signed the informed consent (and assent for pediatric patients), the 
investigator or designee will contact [CONTACT_421935] y (IRT) system to 
obtain a patient identification number (patient ID).  Following full assessment and 
determination that a patient meets all eligibility  criteria, the investigator or designee will 
enroll the patient into the study  using the IRT s ystem.  I nstructions on how to use the I RT 
system will be provided in the study  manual.  No patient will receive stud y drug therap y until 
the entire enrollment process has been completed.
The study -specific I RT reference manual will provide the contact [CONTACT_110275]. 
5.2.Patient Compliance
All doses of investigational product will be administered by  [CONTACT_110443].
The site will complete required dos age Preparation Record located in the study  manual.  The 
use of the Preparation Record is preferred but it does not preclude the use of an existing 
appropriate clinical site documentation sy stem.  The existing clinical site's documentation 
system should ca pture all pertinent/required information on the preparation and 
administration of the dose.  This may  be used in place of the Preparation Record after 
approval from the [COMPANY_007] monitor.
5.3.Investigational Product Supplies
Study  centers will receive a suppl y ofGO after site activation.  Resupplies will be made 
during the course of the study .  The stud y monitor should be contact[CONTACT_421936].
5.3.1. Dosage Form(s) and Packaging
GO for injection is supplied as a white to off -white, unpreserved , lyophilized cake or powder 
in a single -dose 20- mL TypeI amber glass vial with rubber closure and flip -off cap.  Vials 
will be labeled in accordance with local requirements.
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, [ADDRESS_532583] Manual (I P manual), for instructions on how to prepare the 
investigational product for administration.  I nvestigational product should be prepared and 
dispensed by  [CONTACT_274234] 
(eg,physician, nurse, physician’s assistant, nurse practitioner, pharmacy assistant/technician, 
or pharmacist) as allowed by  [CONTACT_5737], state, and institutional guidance. 
5.4.Administration
5.4.1. Administration of the Premedic ation
Premedication is required for all patients.
Patients will be pre- medicated with acetaminophen 650 mg orally and diphenhy dramine 
50mg orally  or intravenously  1hour prior to GO dosing and 1 mg/kg methylprednisolone or 
an equivalent dose of an alterna tive corticosteroid within 30 minutes prior to infusion of GO 
(given prior to GO infusion may  ameliorate infusion -related s ymptoms).
Follow standard practice of the institution to prevent tumor ly sis sy ndrome.
Vital signs should be monitored during infusio n and for 2 hours following infusion.
5.4.2. Administration of GO
Three doses of GO 3 mg/m2(up to one vial per dose) will be administ ered at investigational 
site as a 2 -hour intravenous infusion after premedication on Day s1, 4, and 7 at each cycle. 
Patients wi ll receive 1 or 2 cy cles of GO. The second cy cle of GO will be allowed at the 
investigator’s discretion for patients who meet selected dosing criteria after the first cy cle.
(seeSection 7.5).
Use appropriate aseptic technique for the reconstitution and dilution procedures.  Protect the 
reconstituted and diluted GO solution from light.  See the IP manual for instructions on how 
to administer GO.
5.4.3. Dosage Modification for Toxicities
Every  effort should be made to administer study  medication on the planned dose and 
schedule.  Patients are to be instructed to notify  investigators at the first occurrence of 
any adverse s ymptom.  In the event of multiple toxicities, dose modification should 
be based o n the worst toxicity  observed. 
Full recovery  from hematologic toxicities is not a requirement for administration of the 
second or third dose on Day 4 or 7, respectively .  
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 31In the event of non -hematologic toxicities, dosing may  be delay ed, omitted or 
discontinued as described below ( Table 3) by [CONTACT_421937], AST, AL T,and o ther severe or life -threatening non- hematologic toxicities 
through recovery  from treatment- related toxicitie s. 
In the event of persistent hematologic toxicities after Cy cle 1, conditional Cycle2 
dosing may  be delay ed or discontinued as described below ( Table 3) by [CONTACT_421938]- related toxicities.
Table 3. Dosage Modifications for Non hematologic and Hematologic Toxicities
Non-hematologic Toxicities Recommended Action s
VOD/SOS Discontinue GO. 
Total bilirubin greater than 2×ULN, 
or AST and/or ALT greater than 
2.5×ULNDelay treatment with GO until recovery of total bilirubin to less 
than or equal to 2 × upper normal limit (ULN) and AST and 
ALT to less than or equal to 2.5 × ULN prior to each dose.
Omit scheduled dose if delayed more than 2 days between 
sequential infusions.
Infusion -related reactions Interrupt the infusion and institute appropriate medical 
management.
Adm inister acetaminophen, diphenhydramine and/or 
methylprednisolone, if needed.
Provide supportive care measures as needed.
For mild, moder ate or severe infusion related reactions, once 
symptoms resolve, consider resuming the infusion at no more 
than half the rate at which the reaction occurred.  Repeat the 
procedure above in the event of recurrence of symptoms.
Perm anently discontinue GO upo n occurrence of a severe 
infusion reaction or for any life- threatening infusion reaction. 
Other severe or life- threatening 
non-hematologic toxicitiesDelay treatment with GO until recovery to a severity of no more 
than mild (Grade 1).
Omit scheduled dos e if delayed more than 2 days between 
sequential infusions.
Hem atologic Toxicities Recommended Action s
Persistent thrombocytopenia If platelet count does not recover to greater than or equal to 
50,000 /µL within [ADDRESS_532584] 
cycle, DO NOT administer the 2ndcycle .*
Persistent neutropenia If neutrophil count does not recover to greater than or equal to 
1,000/µL within [ADDRESS_532585] 
cycle, DO NOT administer the 2ndcycle .*
* except in pati ents with the bone marrow blasts 5%,  the decrease in neutrophils and platelets thought to be due to the 
underlying leukemia .
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, [ADDRESS_532586] once reconstituted 
and/or diluted. 
Any storage conditions stated in the SRSD will be superseded by  [CONTACT_346259].
Site sy stems must b e capable of measuring and documenting (for example, via a log), at a 
minimum, daily  minimum and maximum temperatures for all site storage locations (as 
applicable, including frozen, refrigerated, and/or room- temperature products).  This should 
be captured from the time of investigational product receipt throughout the study .  Even for 
continuous- monitoring sy stems, a log or site procedure that ensures active evaluation for 
excursions should be available.  The intent is to ensure that the minimum and maximum 
temperature is checked each business day  to confirm that no excursion occurred since the last 
evaluation and to provide the site with the capability  to store or view the minimum/maximum 
temperature for all non- working day s upon return to normal operation s.  The operation of the 
temperature monitoring device and storage unit (for example, refrigerator), as applicable, 
should be regularl y inspected to ensure they  are maintained in working order. 
Any excursions from the product label storage conditions should be reported to [COMPANY_007] upon 
discovery .  The site should actively  pursue options for returning the product to the storage 
conditions described in the labeling, as soon as possible.  Deviations from the storage 
requirements, including any  actions taken, must be documented and reported to [COMPANY_007]. 
Once an excursion is identified, the investigational product must be quarantined and not used 
until [COMPANY_007] provides permission to use the investigational product.  It will not be considered a 
protocol deviation if [COMPANY_007] approves the use of the investigational product after the 
temperature excursion.  Use of the investigational product prior to [COMPANY_007] approval will be 
considered a protocol deviation.  Specific details regarding information the site should report 
foreach excursion will be provided to the site.
Receipt of materials, door opening and closing, and other routine handling operations where 
the products are briefl y out of the temperature range described in the labeling are not 
considered excursions.
5.6.Investi gational Product Accountability 
The investigator site must maintain adequate records documenting the receipt, use, loss, or 
other disposition of the investigational product supplies.  All investigational products will be 
accounted for using a drug accountabilit y form/record. 
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, [ADDRESS_532587] (eg, at the site).  If destruction is authorized to take place at the investigator sit e, the 
investigator must ensure that the materials are destroy ed in compliance with applicable 
environmental regulations, institutional policy , and any  special instructions provided by  
[CONTACT_4618], and all destruction must be adequatel y documented.
5.7.Concomitant Treatment(s)
All concomitant medications required to clinicall y manage patients while they  are receiving 
GO therap y are permitted, including any  palliative and supportive care for cancer related 
symptoms.  Investigational drugs, anti- cancer therapy  (except hydroxyurea as cy toreduction), 
and radiation (eg, cranial irradiation for CNS leukemia) are prohibited 2 weeks prior to study  
entry , during the GO treatment period, and before the determination of remission status by  
[CONTACT_167666] (BM) assessment. 
The pati ents treated with medications that are known to predispose to Torsades de Pointes 
should discontinue the drugs at least [ADDRESS_532588] -GO period, but allowed after EOT visit.  Refer to Appendix 4
for assessing drugs known to predispose to Torsades de Pointes.
All concomitant medications, including prescription and nonp rescription drugs, nondrug 
treatment, and dietary  supplements and herbal preparations, will be entered on the case report 
form (CRF).  Concomitant medications and treatments will be recorded from [ADDRESS_532589] dose of study  treatment or starting 
subsequent anticancer therap y (eg, consolidation or conditioning regimen).
6. STUDY PROCEDURES 
The enrollment (stud y entry) day is defined as Day 1, when patient identifier is assigned with 
the first GO dosed.
6.1.Screening
Informed consent document (I CD) approved by  [CONTACT_3551] (IRB) or 
Independent Ethics Committee (IEC) must be signed and dated before an y study -specific 
procedures are conducted.  Screening procedures for evaluating eligibility  and baseline data 
will be completed within 28 days prior to dosing on Day 1 unless otherwise noted. 
The following will be collected at screening:
Sign informed consent form and obtain documentation of assent at screening for those 
patients under age 18 (or as specified per local policy /laws).
Review study  eligibility  (inclusion and exclusion criteria).
Gemtuzumab Ozogamicin (MYLOTARG ™)
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 34•Evidence of CD33 positivity for eligibility at screening, eg, by [CONTACT_137766][INVESTIGATOR_421911] a validated assay and obtained within 28 days of enrollment will be collected and recorded in the CRF.  Surface CD33 expression should be measured by [CONTACT_4133] (flow-activated cell sorting, FACS); immunohistochemistry (IHC) analysis is allowed in patients with (1) dry tap; or (2) if BM specimen is inadequate and/or with insufficient circulating blasts for FACS.  
 
•Medical history: To be collected within [ADDRESS_532590] dose.  
•Chronic conditions and/or medical history of significance including alcohol use 
and relevant radiation and surgical procedures; 
•Any other previous cancer diagnosis; 
•Patients with prior HSCT are allowed in the study but those with history of 
VOD/SOS are not allowed.  Medical history must be reviewed for evidence of 
VOD/SOS (eg, weight gain, elevated bilirubin, tender hepatomegaly, and ascites may indicate underlying VOD/SOS), especially if a patient received high-dose chemotherapy followed by [CONTACT_59513]; 
•Current disease: Initial AML diagnosis, relevant information for conclusive 
morphologically documented, refractory or relapsed CD33-positive AML, Eastern 
Cooperative Oncology Group performance status (ECOG PS) will be assessed.  (Definition of refractory and relapsed AML as per ELN 2017 recommendation,
5
seeAppendix 5 ). 
•Focused physical examination performed with clinical judgment evaluating potential 
areas of AML relapse and any clinically significant abnormalities which may include 
the following body systems: general appearance, skin, head/eyes/ears/nose/throat, heart, lungs, testes, abdomen, extremities, neurological, back/spi[INVESTIGATOR_1304], and lymph nodes; including worsening of medical history conditions.
•Imaging Assessment: Patients with suspected extramedullary disease will have 
imaging assessment (eg, computed axial tomography [CAT] or magnetic resonance 
imaging [MRI]) of relevant sites.
•Vital signs including height, weight, blood pressure, pulse, and temperature.  ECOG 
PS will also be assessed. 
•Laboratory evaluations as described in Section 7.4, Appendix 3 , and Schedule of 
Activities (Table 1 ).CCI
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 35For women of childbearing potential, a beta -human chorionic gonadotrop in (-hCG) 
urine or serum pregnancy  test must be conducted as specified in Section 7.7.  
ECG at screening will be collected in triplicate within 28 days prior to enrollment .  
The results will be read and interpreted at the investigational site for eligibility  
determination; results of QTcF assessment are to be available prior to enrollment .
Patients may  beenrolled following successful completion of the pre -study  
assessments, screening procedur es, and confirmation of eligibility . 
Evaluations of HIV and hepatitis B serological tests and hepatitis C tests will be 
conducted ( seeAppendix 2).
Adverse events should be documented and recorded using NCI  CTC AE version 4.03 
(see Section 8).  
6.2.Study Period 
The total study period at each cy cle is comprised of following periods:
GO Treatment: Starts with the first dose of GO (Day 1) and ends with the last dose of 
GO (usuall y Da y 7). 
Post-GO Period: Starts on the day  after the last dose of GO and ends on [ADDRESS_532591] dose of GO or start of subsequent anticancer therapy , including consolidation 
and/or conditioning regimen.  This period ends w ith End-of- Treatment (EOT) visit.
If the optional secon d cycle of GO is administered, the same GO Treatment and Post-
GO Periods are repeated starting once when C ycle [ADDRESS_532592] dose of GO.   This 
period ends with End-of- Treatment (EOT) visit.
Follow -up Period: Starts on the day  after EOT visit and ends when a patient 
completes [ADDRESS_532593].  This is end of 
study  for each patient. 
6.2.1. GO Treatment
Each cy cle include san active GO treatment phase (Day s 1,4, and 7) and a post GO treatment 
phase (Day  10 to 21).
The second cy cle isallowed at the investigator’s discretion for patients who meet the 
following dosing criteria after C ycle 1(refer also to Table 3describing hematologic 
toxicities): Bone marrow with a decrease of blast percentage to at least 25%, or a decrease of 
pretreatment blast percentage b y at least 50% ;andblood count with neutrophils 1,000/µL  
and platelets 50,000/µL, except in patients with the bone marrow blasts 5%,the decrease 
in neutrophils and platelets thought to be due to the underl ying leukemia. 
Gemtuzumab Ozogamicin (MYLOTARG ™)
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 36Patients who don’t meet these criteria after the first cycle of GO are not allowed to receive 
the 2ndcycle. Cycle [ADDRESS_532594] dose of GO 
(ie, Cycle 1 Day 7).
6.2.2. Cycle 1
[IP_ADDRESS]. Cycle 1 Day 1 (GO Treatment)
•On Day 1 patients may be admitted at the site for 24 hours for 
pharmacokinetic/pharmacodynamic (PK/PD) sampling at investigator’s discretion.  
Hospi[INVESTIGATOR_421912] [ADDRESS_532595] of practice and investigator judgment. If there is prolongation of hospi[INVESTIGATOR_059], consider if SAE criteria are met (see Section 8.2.4 ). 
•Laboratory specimen will be collected per the Schedule of Activities (and assessed 
perSection [ADDRESS_532596] a blood sample collected prior to GO administration for the measurement of  immunogenicity (antibodies to GO [ADA] and neutralizing antibody [NAb]). 
 
•Patients will be weighed for body surface area (BSA) calculation. 
•Physical examination (PE) performed with clinical judgment evaluating potential 
areas of AML relapse and any clinically significant abnormalities which may include 
the following body systems: general appearance, skin, head/eyes/ears/nose/throat, heart, lungs, testes, abdomen, extremities, neurological, back/spi[INVESTIGATOR_1304], and lymph nodes; including worsening of medical history conditions.
•Vital signs including blood pressure, pulse , and body temper ature will be performed 
prior to GO infusion and 2 hours after the infusion is complete (see Table 1 ). ECOG 
PS assessment will be conducted if acceptable screening assessment is not done within 7 days prior to the start of investigational drug.  
•Pre-medication should be given before GO infusion.  See Section 5.4.1 and 
Section 5.4.2 for administration of premedication and GO, respectively.
•Electrocardiograms (ECGs) will be collected in all patients according to Schedule of 
Activities (Table 2 ) and as described in Section 7.1 .  The ECGs will be collected in 
triplicate (3 consecutive ECGs approximately 2 minutes apart).  Predose ECGs will be performed prior to GO dosing, after administration of premedications.  Triplicate ECGs will also be performed prior to selected serial PK draws, around the time when the C
maxis expected and immediately before the end of the infusion, ie, prior to the 
Hour 2 PK sample collection (within 15 minutes).3C
C
I
Gemtuzumab Ozogamicin (MYLOTARG ™)
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 37 
 
•Pharmacokinetic (all patients)  
 PK collections will include predose (Hour 0), 
Hour 1, 2, 4, 6, and 24 as described in Schedule of Activities (Table 2 ).   
  Adverse events 
should be documented and recorded using NCI CTCAE version 4.03 (see Section 8 ).
•Concomitant medications and treatments will be recorded.  
[IP_ADDRESS]. Cycle 1 Day 4 and Day 7 (GO Treatment)
•Laboratory tests, PE, and vital signs will be conducted as described in Schedule of 
Activities (Table 1 ). Vital signs will also be performed 2 hours after the infusion is 
complete. 
•For the dose calculation and adjustment of GO, if the patient experiences a weight 
loss or gain >10% from the prior record of weight, the body surface area (BSA) and 
the amount of GO required for dose preparation must be re-calculated (maximum dosage up to one vial). 
•Full recovery from hematologic toxicities is not a requirement for administration of 
the second or third dose on Days 4 and 7, respectively. 
•Pre-medication should be given before dosing.  See Section 5.4.1 and Section 5.4.2
for administration of premedication and GO, respectively.  
•Pharmacokinetic (all patients  
and triplicate ECGs 
will be collected according to Schedule of Activities (Table 2 ).  If the dosing day is 
delayed beyond Day 4, these samples are to be collected on the day of dosing.
•Adverse events should be documented and recorded using NCI CTCAE version 4.03 
(see Section 8 ).
•Concomitant medications and treatments will be recorded.  
[IP_ADDRESS]. Cycle 1 Day 10 (Post-GO Period)
•Laboratory tests, PE, body weight, and vital signs will be conducted according to 
Schedule of Activities (Table 1 ).C
CI
CCI
CCI
CCI
Gemtuzumab Ozogamicin (MYLOTARG ™)
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 38•Pharmacokinetic (all patients), pharmacodynamic (only for patients 18 years or 
older), and metabolic profiling (only for patients 18 years or older) samples will be 
collected according to Schedule of Activities (Table 2 ).
•Patients with suspected extramedullary disease will have imaging assessment 
(eg, CAT or MRI) of all known disease sites.
•Adverse events should be documented and recorded using NCI CTCAE version 4.03 
(see Section 8 ).
•Concomitant medications and treatments will be recorded.  
[IP_ADDRESS]. Cycle 1 Days 15 and 21 (Post-GO Period)
•Laboratory tests (except CBC and differential counts) will be conducted according to 
Schedule of Activities (Table 1 ).
•Starting with Day 15, CBC and differential counts will be examined 3 times a week 
until having determination of remission status (see Section 7.5 ); subsequently CBC 
and differential counts will be collected once weekly until EOT visit (ie, [ADDRESS_532597] dose of GO) or until start of subsequent anticancer therapy, eg, Cycle 2, consolidation and/or conditioning regimen (see Schedule of Activities Table 1 ).
•Pharmacokinetic (all patients)  
 according to Schedule of Activities (Table 2 ). 
•Blood sample will be collected for the measurement of antibodies to GO (ADA) and 
neutralizing antibody (NAb) on Days 15 and 21.
•Patients with extramedullary disease during screening or clinically suspi[INVESTIGATOR_421913] (and biopsy if applicable) will 
have imaging assessment (eg, CAT or MRI). (Day 21)
•Efficacy evaluation and determination of remission status will be assessed by 
[CONTACT_421939][INVESTIGATOR_1516] (and biopsy if applicable) after recovery of blood counts is observed, typi[INVESTIGATOR_421914] 21 and Day 28. This evaluation should be conducted prior to Cycle 2 (if administered) or EOT (ie, [ADDRESS_532598] the dose of GO).
•Adverse events should be documented and recorded using NCI CTCAE version 4.03 
(see Section 8 ).
•Concomitant medications and treatments will be recorded.  CCI
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 396.2.3. Cycle 2
The second cy cle will be allowed at the investigator’s discretion for patients who meet 
selected dosing criteria after Cy cle 1 ( seeSection 7.5). Cycle [ADDRESS_532599] dose of GO ( ie, Cycle 1 Day  7).
[IP_ADDRESS]. Cycle 2 Day 1
On Day 1 patients may  be admitted at the site for 24 hours as per investigator’s 
discretion.  Hospi[INVESTIGATOR_421915] [ADDRESS_532600] practice and 
investigator judgment. If there is prolongation of hospi[INVESTIGATOR_059], consider if SAE 
criteria are met (see Section 8.2.4 ).
Laboratory  specimen will be collected per the Schedule of Activities (Table 1)and 
assessed per Section [ADDRESS_532601] be checked before dosing.  Patients will be we ighed for BSA calculation.
Physical examination (PE) performed with clinical judgment evaluating potential 
areas of AML relapse and any  clinicall y significant abnormalities which may include 
the following body  systems: general appearance, skin, head/ey es/ears/nose/throat, 
heart, lungs, testes, abdomen, extremities, neurological, back/spi[INVESTIGATOR_1304], and l ymph 
nodes; including worsening of medical history  conditions.
Vital signs including blood pressure, pulse and temperature will be performed prior to 
GO infusion a nd 2 hours after the infusion is complete (see Table 1).
Pre-medication should be given before GO infusion.  Section 5.4.1 and Sectio n 5.4.2
for administration of premedication and GO, respectivel y.
Electrocardiograms (ECGs) will be collected in all patients according to Schedule of 
Activities (Table 2) and as described in Section 7.1.  The ECGs will be collected in 
triplicate (3 consecutive ECGs approximatel y 2minutes apart).  Predose ECGs will 
be performed prior to GO dosing, after administra tion of premedications.  Triplicate 
ECGs will also be performed prior to selected serial PK draws, around the time when 
the C maxis expected and immediately before the end of the infusion, ie, prior to the 
Hour 2 PK sample collection (within 15 minutes).3
PK collections (all patients) will include predose (Hour 0) and Hour 2 as described in 
Schedule of Activities (Table 2).  
Adverse events should be documented and recorded using NCI  CTCAE version 4.03 
(see Section 8).
Concomitant medications and treatments will be recorded.  
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Cycle 2 Day 4 and Day 7 (GO Treatment)
Laboratory  tests, PE, and vital sig ns will be conducted as described in Schedule of 
Activities (Table 1).  Vital signs will also be performed 2 hours after the infusion is 
complete. 
For the dose calculation and adjustment of GO, if the pat ient experiences a weight 
loss or gain >10% from the prior record of weight, the body  surface area (BSA) and 
the amount of GO required for dose preparation must be re -calculated (Maximum 
dosage will be up to one vial). 
Full recovery  from hematologic toxic ities is not a requirement for administration of 
the second or third dose on Day 4 or7, respectively . 
Pre-medication should be given before dosing.  See Section 5.4.1 and Section 5.4.2
for administration of premedication and GO, respectivel y.  
Pharmacokinetic (all patients) and triplicate ECGs will be collected on Day 7 
according to Schedule of Activities (Table 2).  If the dosing day  is delay ed bey ond 
Day 4, these samples are to be collected on the day  of dosing.
Adverse events should be documented and recorded using NCI  CTCAE version 4.03 
(see Section 8).
Concomitant medications and treatments will be recorded.  
[IP_ADDRESS]. Cycle 2 Day 10 (Post -GO Period)
Laboratory  tests will be conducted according to Schedule of Activities (Table 1).
Patients with suspected extramedullary  disease will have imaging assessment 
(eg,CAT or MRI) of all known disease sites . 
Adverse events should be documented and recorded using NCI CTCAE version 4.03 
(see Section 8).
Concomitant medications and treatments will be recorded.  
[IP_ADDRESS]. Cycle 2 Days 15 and 21 (Post -GO Period)
Laboratory  tests (except CBC and differential counts) will be conducted according to 
Schedule of Acti vities (Table 1). 
Starting with Day 15, blood cell and differential counts will be examined 3 times a 
week until having determination of remission status (see Section 7.5); subsequently  
CBC and differential counts will be collected once weekl y until EOT visit 
(ie,36days after the last dose of GO) or until start of subsequent anticancer therapy , 
eg,consolidation and/or conditioning regimen (see Schedule of Activities Table 1).
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 41Blood sample will be collected for PK assessment and the measurement of antibodies 
to GO (ADA) and neutralizing antibody  (NAb) on Day s15 and 21.
Patients with extramedullary  disease during scr eening or clinically  suspi[INVESTIGATOR_421916] (and biopsy  if applicable) will 
have imaging assessment ( eg, CAT or MRI). 
Determination of remission status will be assessed by [CONTACT_421940][INVESTIGATOR_1516] (and biopsy  if applicable) after recovery of blood counts is 
observed, , t ypi[INVESTIGATOR_1306] y between D ay 21 and D ay 28.This evaluation should be 
conducted prior to EOT (ie ,[ADDRESS_532602] dose of GO ). 
Adverse events should be document ed and re corded using NCI  CTC AE version 4.03 
(see Section 8).
Concomitant medications and treatments will be recorded.  
6.2.4. The End -of-Treatment (EOT) Visit ([ADDRESS_532603] Dose of GO)
This visit i s required for all patients.  I t occurs [ADDRESS_532604] dose of GO.
However, in the event that a patient requires initiation of a consolidation treatment or 
another anti -cancer therapy , the end -of-treatment visit, including procedures 
(laboratory  tests, PE, sampling for PK and ADA/NAb assay s), should be performed 
before the initiation of a consolidation treatment or subsequent anti -cancer therapy .  
Adverse events, safet y laboratory  tests, and associated concomitant medications must 
continue to be col lected in the CRF through at least [ADDRESS_532605] dose of GO 
or start of subsequent therapy, eg, consolidation and/or conditioning regimen, 
whichever occurs first. 
Adverse Event (AE) Assessments should be documented and recorded at each visit 
using NCI  CTCAE version 4.03 up to EOT visit, or start of subsequent anticancer 
therap y, eg, consolidation and/or conditioning regimen, whichever occurs first. 
Concomitant medications and treatments will be recorded up to [ADDRESS_532606] 
dose of study  treatment or starting subsequent anticancer therapy  (eg, consolidation or 
conditioning regimen).
EOT visit procedures and tests include the following:
Blood sample collection for PK assessment and ADA/NAb measurement;
Limited ph ysical examination, with cli nical judgment to evaluate potential areas 
of AML relapse and an y clinically  significant abnormalities which may  include 
the following body  systems: general appearance, skin, head/ey es/ears/nose/throat, 
heart, lungs, testes, abdomen, extremities, neurologi cal, back/spi[INVESTIGATOR_1304], and l ymph 
nodes; including worsening of medical history  conditions;
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 42Laboratory  evaluations, including pregnancy  test, according to the Schedule of 
Activities (Table 1).
Disease assessment for final determination of remission status should be 
conducted no later than [ADDRESS_532607] dose of GO (EOT) or/and prior to the 
start of subsequent anticancer therap y (eg, consolidation and/or conditioning 
regimen).
6.2.5. Follow -up Period
Each patient will visit the study  site every  12weeks during study  duration of 12 months after 
enrollment; for procedures to be followed during these visits see Schedule of Activities
(Table 1).  For any  patients who may  not be able to visit the study  site at the protocol 
designated time, telephone contact [CONTACT_421928] -up for stud y 
duration of 12 months.  Any  occurrences of VOD/SOS will be recorded in the CRF for entire 
study  duration of [ADDRESS_532608]. 
Following information will be collected during the follow -up period:
Blood sample collection for ADA/NAb measurement for patients known to be ADA 
positive at the EOT visit: Samples will be collected every  12 weeks until ADA titers
that are no longer detectable, return to baseline , or stabilize at a level acceptable to 
the investigator and sponsor ;or up to [ADDRESS_532609].
Subsequent antican cer therapy  information (eg, consolidation and/or conditioning 
regimens, ty pe of HSCT).
Concomitant medication for graft -versus -host disease (GVHD) proph ylaxis and 
VOD/SOS prophy laxis.
Survival including causes of death. 
6.3.Patient Withdrawal 
Reasons for di scontinuation of study  treatment may  include:
Withdrawal of consent and/or assent;
Adverse events of u nacceptable toxicity as determined by  [CONTACT_093], or n eed for 
treatment delay  or continuous interruption of the second stud y dose beyond 2 days 
after the scheduled day  of dosing due to study  treatment related non -hematologic 
toxicity; 
Global deterioration of health status requiring discontinuation;
Lost to follow -up;
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 43Patient refused further treatment ;
Study  terminated by  [CONTACT_2728] ;
Death .
Withdrawal of consent:
Patients who request to discontinue study  treatment will remain in the study  and must 
continue to be followed for protocol specified follow -up procedures.  The only  exception to 
this is when a patient specificall y withdraws consent for an y furthe r contact [CONTACT_421941].  Patients should 
notify  the investigator in writing of the decision to withdraw consent from future follow -up, 
whenever possible.  The withdrawal of cons ent should be explained in detail in the medical 
records b y the investigator, as to whether the withdrawal is onl y from further receipt of 
investigational product or also from stud y procedures and/or posttreatment study follow -up, 
and entered on the appropriate CRF page.  In the event that vital status (whether the patient is 
alive or dead) is being measured, publicl y available information should be used to determine 
vital status only  as appropriately  directed in accordance with local law.
Lost to follow- up: 
All reasonable efforts must be made to locate patients to determine and report their ongoing 
status.  This includes follow -up with persons authorized by  [CONTACT_421942].  Lost 
to follow -up is defined by  [CONTACT_53981] y to reach the patient afte r a minimum of 2 documented 
phone calls, faxes, or e -mails as well as lack of response b y the patient to 1 registered mail 
letter.  All attempts should be documented in the patient’s medical records.  If it is 
determined that the patient has died, the site will use locally  permissible methods to obtain 
the date and cause of death.  I f the investigator’s use of a third -party representative to assist 
in the follow -up portion of the study  has been included in the patient’s informed consent, 
then the investigator may use a sponsor- retained third -party representative to assist site staff 
with obtaining the patient’s contact [CONTACT_310800] -up portion of the study .  The site staff and representative wi ll consult 
publicly  available sources, such as public health registries and databases, in order to obtain 
updated contact [CONTACT_3031].  I f, after all attempts, the patient remains lost to follow -up, then 
the last -known- alive date as determined by  [CONTACT_421943]’s medical records.
Patients may  withdraw from the study  at an y time at their own request, or they  may  be 
withdrawn at an y time at the discretion of the investigator or sponsor for safety (see also th e 
Withdrawal From the Study  Due to Adverse Events Section 8.1.3 ) or behavioral reasons, or 
the inability  of the patient to comply  with the protocol -required schedule of study visits or 
procedures at a given study  site. 
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, [ADDRESS_532610]’s medical record.  In an y circumstance, every  effort 
should be made to document patient outcome, if possible.  The investigator should inquire 
about the reason for withdrawal, request that the patient return for a final visit, if applicable, 
and follow up with the patient regarding an y unresolved adverse events.
If the patient withdraws from the study , and also withdraws consent for disclosure of future 
information, no further evaluations should be performed, and no additional data should be 
collected.  The sponsor may retain and continue to use any  data collected before such 
withdrawal of consent.
Patients who withdraw from the study  may  be replaced at the discretion of the investigator 
upon consultation with the sponsor.
7.ASSESSMENTS
Every  effort should be made to ensure that the protocol -required tests and procedures are 
completed as described.  However, it is anticipated that from time to time there may  be 
circumstances outside of the control of the investigator that may  make it unfeasible to
perform the test.  In these cases the investigator will take all steps necessary to ensure the 
safet y and well -being of the patient.  When a protocol -required test cannot be performed, the 
investigator will document the reason for this and any corrective and preventive actions that 
he or she has taken to ensure that normal processes are adhered to as soon as possible.  The 
study  team will be informed of these incidents in a timely  manner.
For samples being collected and shipped, detailed collection, proces sing, storage, and 
shipment instructions and contact [CONTACT_19987] .
7.1.Electrocardiogram Assessment 
7.1.1. QT Interval Prolongation
As indicated in the Schedule of Act ivities (Table 2), triplicate ECGs will be performed at 
screening, baseline (prior to dose on Day 1) and on each day  of dosing (Day s1, 4, and 7 of at
cycle).  ECGs will be paired with PK blood sampl ingand collected immediately  prior to the 
PK blood sample collection, such that the blood sample is collected at the nominal planned 
time.  I deally , the patient will be supi[INVESTIGATOR_421908] a semi recumbent position for the 
entire infusion and for both pre and post infusion ECGs.  To minimize artifact, the patient 
should not change position between the pre and post infusion ECGs.  I f a patient experiences 
a cardiac or neurologic AE (specifically  syncope, dizziness, seizures, or stroke) triplicate 
ECGs should be obtained at the time of the event.  Additional ECGs will be performed as 
clinically  indicated for patient safet y monitoring and documentation stored in the source 
documents.
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 45A 12 -lead (with a 10- second rhy thm strip) tracing will be used for all ECGs.  ECG 
measurements will inclu de PR interval, QT interval, RR interval, and QRS complex.  For 
triplicate measures, at each time point, three consecutive ECGs will be performed 
approximatel y 2minutes apart, but within [ADDRESS_532611] intervals automatically . 
All ECGs will be sent to the ECG core laboratory  for independent reading and interpretation. 
7.1.2. Core Laboratory Manual Measurement for ECGs/QTc
Core ECG laboratory , which acts like a central l aboratory  (vendor) for reading ECGs, 
performing manual interval measurement will carry  out independent reading and 
interpretation of QTc interval.3
The ECG core laboratory will follow the below directions for t he ECGs assessments:
Blinding of ECG reader to time, and day  identifiers.
Review of ECGs from a particular patient should be performed b y a single reader.
Pre-specification of the lead for interval measurements.
Baseline and on -treatment ECGs should be bas ed on the same lead.
7.2.Pharmacokinetics Assessment 
7.2.1. Pharmacokinetic Samples 
Blood samples for pharmacokinetic analy siswillbe collected from all participating patients 
at the times indicated in Schedule of Activities (Table 2), during infusion and from the arm 
opposite to the infusion site, according to the procedures in the lab manual .
Later samples (Day s10 to EOT visit) are collected primarily  to assess immunogenicity  (with 
a companion PK sample).
All efforts will be made to obtain the pharmacokinetic samples at the exact nominal time 
relative to dosing.  However, some flexibility in sampling times has been provided to allow 
for variation in assessment schedules.  Samples obtained within the specified t ime windows 
will not be captured as a protocol deviation, as long as the exact time of the sample collection 
is noted on the source document and data collection tool (eg, CRF).  During the trial, actual 
collection times may  change but the number of samples will remain the same.[ADDRESS_532612] ope rating procedures.  Details regarding the storage and shippi[INVESTIGATOR_421917].
Gemtuzumab Ozogamicin (MYLOTARG ™)
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 46 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.3. Immunogenicity
Anti-drug antibody (ADA) samples will be collected according to Schedule of Activities
(Table 2 ). Procedures related to the handling, storage and shipments will be described in the 
laboratory manual.
Samples will be analyzed for anti-drug antibodies using an electrochemiluminescent method, 
with a tiered approach of screening, confirmation, titer determination and additional specificity (characterization in the presence of purified hP67.6 (naked antibody) and Calicheamicin (Payload). Samples that test positive for ADA may be further characterized for specificity to the unconjugated naked antibody and Payload and to determine whether neutralizing antibodies (NAb) are present.
Samples collected for detecting ADA and NAb will be retained in accordance with local 
regulations and, if not used in the timeframe, will be destroyed.  Additional exploratory testing of samples may be performed to further characterize the ADA response.CCI
CCI
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 477.4.Safety Assessments 
Safety  assessments include adverse events (AEs) graded according to the National Cancer 
Institute Common Terminology  Criteria for Adverse Events ( NCI CT CAE , version 4.03), 
clinical examination (including blood pressure and pulse), ECGs, and laboratory  tests 
(hematology , chemistry , coagulation and urinal ysis).
Additional (unscheduled) assessments should be conducted if laboratory  values are abnormal 
(or if clinicall y indicated) and repeated until resolution, until return to baseline, or until NCI  
CTCAE Grade 1.  
Safety  assessments will be conducted until patient discontinues from the study  or as protocol 
specified for [ADDRESS_532613] dose of GO or start of subsequent anticancer therapy  such 
as consolidation and/or conditioning regimen ( Schedule of Activities Table 1).Survival 
status will be collected for the study  duration of 12 months for each pa tient. 
The laboratory  tests specifi ed in Appendix 3will be conducted.
7.4.1. Veno -occlusive Disease Assessments and Sinusoidal Obstruction Syndrome
Patients with prior history  of VOD/SOS will be excluded from enrollm ent.  I nvestigators 
must be vigilant when reviewing medical history  for any  evidence of VOD/SOS that might 
not have been formall y evaluated for diagnosis, and must be rigorous in evaluation to rule out 
presence of an y potential of VOD/SOS at baseline.  VOD /SOS may  present as a constellation 
of signs and sy mptoms such as weight gain, elevated bilirubin, tender hepatomegaly , and 
ascites.  As it is sometimes a complication of high -dose chemotherap y (conditioning therapy ) 
given before HSCT, careful evaluation i n the context of previous and subsequent HSCT is 
essenti al.  Table 4provides European Group for Blood and Marrow Transplantation (EBMT) 
criteria of VOD/SOS for recommended reference.21,[ADDRESS_532614] a hepatology  consultation and work-up 
including (but not limited to) hepatic function test monitoring (eg, AST, ALT, and t otal 
bilirubin), ultrasound evaluation, weight gain monitoring, and active hepatitis evaluation, eg, 
viral autoimmune ,etc.
All cases of VOD/SOS, regardless of causalit y or severit y, must be reported as a SAE within 
the entire stud y duration of 12 months (see Section 8.1.4 ). 
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 48Table 4. EBMT Criteria for VOD/SOS Diagnosis
EBM T Criteria for VOD/SOS Diagnosis in Adults21
Classical VOD/SOS
In the ﬁrst [ADDRESS_532615]
(Baltimore Criteria)Late onset VOD/SOS 
>21Days after HSCT
Bilirubin 2mg/dL and tw o of the following 
criteria must be present:
Hepatomegaly (painful hepatomegaly);
Ascites;
Weight gain >5% from baseline .Classical VOD/SOS beyo nd Day 21,
OR
Histologically proven VOD/SOS ,
OR
Presence of tw o or m ore of the following 
criteria AND hemodynamic or/and ultrasound 
evidence of SOS/VOD:
Bilirubin 2 mg/dL (or 34 mol/L) Painful 
hepatomegaly ;
Weight gain >5% ;
Ascites.
EBM T Criteria for VO D/SOS Diagnosis in Pediatrics21
Nolimitation for time ofonset ofSOS/VOD.
The presence oftwoormore ofthe following :a
Unexplained consumptive andtransfusion -refractory thrombocytopenia ;b
Otherwise unexplained weight gain on three consecutive days despi[INVESTIGATOR_421918] a 
weight gain >5% above baseline value ;
Hepatomegaly (best if con ﬁrmed by [CONTACT_9661]) above b aseline value;c
Ascites (best if con ﬁrmed by [CONTACT_9661]) above baseline value ;c
Rising bilirubin from a baseline value on 3 consecutive days or bilirubin 2mg/dL within 72hours .
a.With the exclusion of other potential differential diagnoses. 
b.1 weight -adjusted platelet substitution/day to maintain institutional transfusion guidelines. 
c.Suggested: imaging ( ultrasonography , CAT ,or MRI) immediately before HS CT to determin e baseline 
value for both hepatomegaly and ascites.
Doppler Ultrasonography for Clinical Suspi[INVESTIGATOR_421919]/SOS
When VOD/SOS is in the differential diagnosis, a right upper quadrant ultrasound with color 
flow Doppler (including resistive indices to hepatic artery  flow and evaluation of hepatic 
venous outflow) should be performed.  In addition, the radiology  report should describe 
common bile duct, the degree of gall bladder wall thickening in millimeters, and the volume 
of ascites should be estimated as clo sely as possible (ie, small and localized, moderate and 
generalized, or large and generalized). 
Assessments and Laboratory Tests
Any of the following assessments, used to diagnose VOD/SOS, should be reported.
Biopsy ; 
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 49Doppler ultrasonograph y; 
Measurement of venous pressures;
Laboratory  tests must include liver function tests (LFTs), eg, total bilirubin, 
AST/AL T, ALK -P (alkaline phosphatase), PT/INR (prothrombin ratio/international 
normalized ratio), aPTT, fibrinogen, and creatinine level.
Risk factors for VOD/SOS or other factors affecting liver function such as GVHD 
prophy laxis and/or treatment, and anti -infectives used as treatment or prophy laxis should be 
reported.  The information on HSCT (eg, allogeneic, matched, or related/unrelated) with 
conditionin g regimens will be collected. 
Management of VOD/SOS
The diagnosis of VOD/SOS, interpretation of severity ,and appropriate management of the 
event will be medicall y determined b y investigator per institutional standard(s). 
Treatment of VOD/SOS must be described and entered into the CRF (eg, defibrotide). 
7.5.Response Assessments
Response assessment will be determined as follows: 
Starting with Day 15, blood cell and differential counts will be examined 3 times a 
week after GO dosing until determination of rem ission status; subsequently  CBC and 
differential counts will be collected once weekl y until EOT visit (ie, [ADDRESS_532616] dose of GO), or until start of Cy cle 2 (if administered) , or until start of subsequent 
therap y (eg, consolidation and/or conditioning regimen ).  
Efficacy  evaluation and determination of remission status by  [CONTACT_421925][INVESTIGATOR_1516] (and biops y if applicable) will be conducted at the end of each cycle after 
blood count recovery  (neutrophils  500/L and platelet 50,000/ L)is observed or at 
a maximum of [ADDRESS_532617] dose of GO regimen.  
A bone marrow aspi[INVESTIGATOR_421920], and a bone 
marrow biops y is also recommended to confirm response and to assess cellularity and 
is required in c ase of a dry  tap.
The second cy cle will be allowed at the investigator’s discretion for patients who meet the 
following dosing criteria after C ycle 1(refer also to Table 3describing hematologic 
toxicities):
Bone marrow with a decrease of blast percentage to at least 25% or a decrease of 
pretreatment blast percentage b y at l east 50% ;and
Gemtuzumab Ozogamicin (MYLOTARG ™)
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 50•Blood count with neutrophils ≥1,000/μL and platelets ≥50,000/μL, except in patients 
with the bone marrow blasts ≥5%, the decrease in neutrophils and platelets thought to 
be due to the underlying leukemia.
Patients who don’t meet these criteria after the first cycle of GO will not be allowed to 
receive the 2ndcycle.
Response will be assessed using European Leukemia Net (ELN 2017) recommendations 
(Table 5).5
Table 5. European Leukemia Net (ELN 2017) Recommendations5
Complete Remission 
(CR)•Bone marrow blasts <5%; absence of circulating blasts and blasts with 
Auer rods; absence of extramedullary disease;
•ANC ≥1x109/L (1000/ μL); platelet count ≥1x109/L (100,000/mL).
CR with incomplete 
hematologic recovery
(CRi)•All CR criteria except for residual neutropenia; ANC <1x109/L 
(1000/μL); or thrombocytopenia; platelet count <1x109/L 
(100,000/mL).
7.6. Survival
Survival status will be followed for all patients for the study duration.  For any enrolled 
patient who may not be able to visit the study site at the protocol designated time, telephone contact [CONTACT_421928]-up, plus collecting cause(s) of death. 
7.7. Pregnancy Testing
For female patients of childbearing potential, a serum or urine pregnancy test, with 
sensitivity of at least 25 mIU/mL and assayed in a certified laboratory, will be performed on 2 occasions prior to starting administration of study medication —once at the start of screening and once at the baseline visit, immediately before starting the study treatment.  Following a negative pregnancy test result at screening, appropriate contraception must be commenced and a second negative pregnancy test result will be required at the baseline visit before the patient may receive the study medication.  Pregnancy tests will be repeated at at the end of study treatment, and additionally whenever 1 menstrual cycle is missed or when potential pregnancy is otherwise suspected.  Additional pregnancy tests may also be undertaken if requested by [CONTACT_110453] (IRBs)/ethics committees (ECs) or if required by [CONTACT_427].  In the case of a positive confirmed pregnancy, the patient will be withdrawn from administration of investigational product but may remain in the study. 
 
 
 
 
CCI
Gemtuzumab Ozogamicin (MYLOTARG ™)
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 51 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
7.9. Imaging Assessments 
•Patients with suspected extramedullary disease will have imaging assessment 
(eg, CAT or MRI) of relevant disease sites during screening.  Imaging assessment 
will be repeated during the post-GO period ( Schedule of Activities Table 1 ).CCI
CCI
CCI
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 52For imaging assessment using Doppler sonography in patients with suspected 
VOD/SOS, please see Section 7.4.1 .
8.ADVERSE EVENT REPORT ING
8.1.Requirements
The table below summarizes the requirements for recording safet y events on the CRF and for 
reporting safety  events on the Clinical Trial (CT) Serious Adverse Event (SAE) Report Form 
to [COMPANY_007] Safety .  These requirements are delineated for 3 ty pes of events: (1) SAEs; 
(2)non-serious adverse events (AEs); and (3) exposure to the investigational product under 
study  during pregnancy  or breastfeeding, and occupational exposure. 
Safety Event Recorded on the CRF Reported on the CT SAE 
Report Form to [COMPANY_007] 
Safety Within [ADDRESS_532618] 
under study  during 
pregnancy  or 
breastfeeding, and 
occupational exposureAll (regardless of whether 
associated with an AE), 
except occupational 
exposureExposure during pregnancy , 
exposure via breastfeeding, 
occupational exposure 
(regardless of whether 
associated with an AE)
All observed or volunteered events regardle ss of treatment group or suspected causal 
relationship to the investigational product will be reported as described in the following 
paragraphs.
Events listed in the table above that require reporting to [COMPANY_007] Safety  on the CT SAE Report 
Form within [ADDRESS_532619] be made immediately , irrespective of the extent of available 
event information.  This time frame also applies to additional new (follow -up) information on 
previously  forwarded reports.  I n the rare situation that the investigato r does not become 
immediately  aware of the occurrence of an event, the investigator must report the event 
within 24 hours after learning of it and document the time of his/her first awareness of the 
event.
For each event, the investigator must pursue and o btain adequate information both to 
determine the outcome and to assess whether it meets the criteria for classification as an SAE 
(see the Serious Adverse Events section below).  In addition, the investigator may  be 
requested b y [COMPANY_007] Safety  to obtain specific follow -up information in an expedited fashion.  
This information is more detailed than that recorded on the CRF.  In general, this will include 
a description of the event in sufficient detail to allow for a complete medical assessment of 
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, [ADDRESS_532620] SAE 
Report Form; additional source documents (eg, medical records, CRF, laboratory  data) are to 
be sent to [COMPANY_007] Safet y ONLY upon reques t.
As part of ongoing safet y reviews conducted b y the sponsor, an y non -serious AE that is 
determined b y the sponsor to be serious will be reported by [CONTACT_74094].  To assist 
in the determination of case seriousness, further information may  be requested from the 
investigator to provide clarity  and understanding of the event in the context of the clinical 
study .
As noted in the Protocol -Specified Serious Adverse Events section ( Section 8.4.1 ), should an 
investigator judge one of the identified protocol -specified SAEs to have a causal relationship 
with the investigational product, the investigator must report the SAE to [COMPANY_007] Safet y within 
24hours of investigator awareness.
8.1.1. Additional Details on Recording Adverse Events on the CRF
All events detailed in the table above will be recorded on the AE page(s) of the CRF.  I t 
should be noted that the CT SAE Report Form for reporting of SAE information is not the 
same as the AE page of the CRF.  When the same data are collected, the forms must be 
completed in a consistent manner.  AEs should be recorded using concise medical 
terminology  and the same AE term should be used on both the CRF and the CT SAE Report 
Form for reporting of SAE information.
8.1.2. Eliciting Adverse Event Information
The investigator is to record on the CRF all directly  observed AEs and all AEs spontaneously  
reported b y the stud y patient/legally acceptable representative.  In addition, each stud y 
patient/le gally  acceptable representative will be questioned about the occurrence of AEs in a 
non-leading manner.
8.1.3. Withdrawal from the Study Due to Adverse Events (see also the Patient 
Withdrawal Section 6.3)
Withdrawal due to AEs should be distinguished from withdrawal due to other causes, 
according to the definition of AE noted below, and recorded on the CRF. 
When a patient withdraws from the study because of an SAE, the SAE must be re corded on 
the CRF and reported, as appropriate, on the CT SAE Report Form, in accordance with the 
Requirements section above.
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 548.1.4. Time Period for Collecting AE/SAE Information
The time period for actively eliciting and collecting AEs and SAEs (“active collection 
period”) for each patient begins from the time the patient provides informed consent, which 
is obtained before the patient’s participation in the study  (ie, before undergoing any  
study -related procedure and/or receiving investi gational product)  through and including a 
minimum of [ADDRESS_532621]. 
For patients who are screen failures, the active collection period ends when screen failure 
status is determined. 
Any patient with VOD/SOS will be monitored for the study  duration of 12 months from 
enrollment as described in Section 7.4.1. 
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety
All SAEs occurring in a patient during the active collection period are reported to [COMPANY_007] 
Safety  on the CT SAE Report Form.
SAEs occurring in a patient after the active collection period has ended are reported to [COMPANY_007] 
Safety  if the investigator becomes aware of them; at a minim um, all SAEs that the 
investigator believes have at least a reasonable possibility  of being related to investigational 
product must be reported to [COMPANY_007] Safety .  Follow up by  [CONTACT_421944] a level acceptable to the investigator, and [COMPANY_007] concurs with that assessment.
If a patient starts a subsequent anticancer therap y (eg, consolidation, and/or conditioning 
regimen, or HSCT), SAEs oc curring during the above -indicated active collection period 
(ie,within [ADDRESS_532622] dose of GO) must still be reported to [COMPANY_007] Safety  irrespective of 
any intervening treatment and causalit y.
Incidence of VOD/SOS will be reported for the entire study  duration of 12 months, 
regardless of causality , or start of subsequent anticancer therapy  (eg, consolidation and/or 
conditioning regimen, or HSCT).  All cases of VOD/SOS must be reported as SAEs 
(recorded on the CRF and CT SAE Report Form).
[IP_ADDRESS]. Recording Non -serious AEs and SAEs on the CRF 
During the active collection period, both non-serious AEs and SAEs are recorded on the 
CRF.
Follow -up by  [CONTACT_47610] a level acceptable to the inve stigator, and [COMPANY_007] concurs with that assessment.
If a patient begins a new anticancer therap y, the recording period for non -serious AEs ends at 
the time the new treatment is started; however, SAEs must continue to be recorded on the 
CRF during the above -indicated active collection period.
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 558.1.5. Causality Assessment
The investigator’s assessment of causalit y must be provided for all AEs (serious and 
non-serious); the investigator must record the causal relationship on the CRF, and report such 
an assessment in ac cordance with the SAE reporting requirements, if applicable.  An 
investigator’s causalit y assessment is the determination of whether there exists a reasonable 
possibility  that the investigational product caused or contributed to an AE; generall y the facts 
(evidence) or arguments to suggest a causal relationship should be provided.  If the 
investigator does not know whether or not the investigational product caused the event, then 
the event will be handled as “related to investigational product” for reportin g purposes, as 
defined b y the sponsor.  If the investigator's causality assessment is “unknown but not 
related” to investigational product, this should be clearl y documented on study  records. 
In addition, if the investigator determines that an SAE is asso ciated with study  procedures, 
the investigator must record this causal relationship in the source documents and CRF, and 
report such an assessment in the dedicated section of the CT SAE Report Form and in 
accordance with the SAE reporting requirements.
8.1.6. Sponsor’s Reporting Requirements to Regulatory Authorities
AE reporting, including suspected unexpected serious adverse reactions, will be carried out 
in accordance with applicable local regulations.
8.2.Definitions
8.2.1. Adverse Events
An AE is an y untoward medical oc currence in a study  patient administered a product or 
medical device; the event need not necessaril y have a causal relationship with the treatment 
or usage.  Examples of AEs include, but are not limited to: 
Abnormal test findings;
Clinically  significant signs and sy mptoms;
Changes in physical examination findings;
Hypersensitivity ;
Drug abuse;
Drug dependency .
Additionally , AEs may  include signs and s ymptoms resulting from:
Drug overdose;
Drug withdrawal;
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 56Drug misuse; 
Drug interactions;
Extravasation;
Exposure during pregnancy  (EDP);
Exposure via breastfeeding;
Medication error;
Occupational exposure.
Worsening of signs and symptoms of the malignancy  under study  should be recorded as AEs 
in the appropriate section of the CRF.  Disease progression assessed by [CONTACT_196361].
8.2.2. Abnormal Test Findings
Abnormal objective test findings should be recorded as AEs when an y of the following 
conditions are met: 
Test result is associated wi th accompan ying symptoms; and/or
Test result requires additional diagnostic testing or medical/surgical intervention; 
and/or
Test result leads to a change in study  dosing (outside of any  protocol -specified dose 
adjustments) or discontinuation from the stud y, significant additional concomitant 
drug treatment, or other therap y; and/or
Test result is considered to be an AE b y the investigator or sponsor.
Merel y repeating an abnormal test, in the absence of an y of the above conditions, does not 
constitute an AE .  An y abnormal test result that is determined to be an error does not require 
recording as an AE.
8.2.3. Serious Adverse Events
A serious adverse event is any  untoward medical occurrence at any  dose that:
Results in death;
Is life -threatening (immediate risk of death);
Requires inpatient hospi[INVESTIGATOR_1081];
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 57Results in persistent or significant disability /incapacity  (substantial disruption of the 
ability  to conduct normal life functions);
Results in congenital anomaly /birth defect.
Or that is considered to be:
An important medical event.
Medical and scientific judgment is exercised in determining whether an event is an important 
medical event.  An important medical event may  not be immediately  life-threatening and/or 
result in death or hospi[INVESTIGATOR_059].  However, if it is determined that the event may  jeopardize 
the patient or may  require intervention to prevent one of the other AE outcomes, the 
important medical event should be reported as serious.  Examples of such events ar e 
intensive treatment in an emergency  room or at home for allergic bronchospasm; blood 
dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059]; or development of drug 
dependency  or drug abuse.
Progression of the malignancy  under stud y (including si gns and sy mptoms of progression) 
should not be reported as an SAE unless the outcome is fatal within the active collection 
period.  Hospi[INVESTIGATOR_196327].  If the malignancy  has a fatal outcome during the study or within the 
active collection period, then the event leading to death must be recorded as an AE on the 
CRF, and as an SAE with Common Terminology  Criteria for Adverse Events (CTCAE) 
Grade 5 (see the Severit y Assessment section).
8.2.4. Hospi[INVESTIGATOR_47575] y initial admission (even less than 24 hours) in a hospi[INVESTIGATOR_31009] , or any  prolongation of an existing admission.  Admission also 
includes transfer w ithin the hospi[INVESTIGATOR_4591]/intensive care unit (eg, from the psy chiatric 
wing to a medical floor, medical floor to a coronary  care unit, or neurological floor to a 
tuberculosis unit).  An emergency  room visit does not necessaril y constitute a hospi[INVESTIGATOR_059]; 
however, the event leading to the emergency  room visit is assessed for medical importance.
Hospi[INVESTIGATOR_4592]:
Rehabilitation facilities;
Hospi[INVESTIGATOR_4593];
Respi[INVESTIGATOR_4594] (eg, caregiver relief);
Skilled nursing facilitie s;
Nursing homes;
Same -day surgeries (as outpatient/same -day/ambulatory  procedures).
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 58Hospi[INVESTIGATOR_4595] a precipi[INVESTIGATOR_74039].  Examples include:
Admission for treatment of a p reexisting condition not associated with the 
development of a new AE or with a worsening of the preexisting condition (eg, for 
workup of a persistent pretreatment laboratory  abnormality );
Social admission (eg, patient has no place to sleep);
Administrative admission (eg, for yearly physical examination);
Protocol -specified admission during a study  (eg, for a procedure required by  [CONTACT_8896]);
Optional admission not associated with a precipi[INVESTIGATOR_4596] (eg, for elective 
cosmetic surgery );
Hosp italization for observation without a medical AE;
Preplanned treatments or surgical procedures.  These should be noted in the baseline 
documentation for the entire protocol and/or for the individual patient;
Admission exclusively  for the administration of blood products.
Diagnostic and therapeutic noninvasive and invasive procedures, such as surgery , should not 
be reported as SAEs.  However, the medical condition for which the procedure was 
performed should be reported if it meets the definition of an SAE. For example, an acute 
appendicitis that begins during the reporting period should be reported if the SAE 
requirements are met, and the resulting appendectomy  should be recorded as treatment of the 
AE.
8.3.Severity Assessment
If required on the AE page of the CRF, the investigator will use the adjectives MILD, 
MODERATE, or SEVERE to describe the maximum intensity  of the AE.  For purposes of 
consistency , these intensity  grades are defined as follows:
MILD Does not interfere with subject's usual function.
MODER ATE Interferes to some extent with subject's usual function.
SEVERE Interferes significantl y with subject's usual function.
Note the distinction between the severit y and the seriousness of an AE.  A severe event is not 
necessarily  an SAE.  For example, a headache may  be severe (interferes significantly  with 
the subject's usual function) but would not be classified as serious unless it met one of the 
criteria for SAEs, listed above.
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 59Investigators should report AEs using concise medical terminology  (verbati m) as well as 
collect on the CRF the appropriate Common Terminology  Criteria for Adverse Events 
(CTCAE) (Version 4.03, Publish Date: 14 June 2010, NCI CTCAE ) listed in the Cancer 
Therap y Evaluation Program.  New protocols of projects that have been utilizi ng a previous 
version may  continue to use that version.
If required on the AE page of the CRF, the investigator will use the following definitions of 
severit y in accordance with the current CTCAE version to describe the maximum intensity  of 
the adverse eve nt.  
Grade Clinical Description of Severit y
0 No change from normal or reference range (This grade is not included in the 
Version 4.03 CTCAE document but may  be used in certain circumstances.)
1 MILD adverse event
2 MODERATE adverse event
3 SEVERE adverse event
4 LIFE -THREATENING consequences; urgent intervention indicated
[ADDRESS_532623] and an event specified below, these events should not be reported to [COMPANY_007] Safety  by 
[CONTACT_421945].  These events are anticipated to occur commonly  in a population 
with AML .  However, these events should still be recorded as adv erse events on the case 
report Form (CRF).
Protocol -specified SAEs that will not normally  be reported to [COMPANY_007] Safet y in an expedited 
manner: 
Febrile neutropenia (unless Grade 5).
Neutropenic sepsis (unless Grade 5).
Should an aggregate analysis indicate that these prespecified events occur more frequently  
than expected, eg, based on epi[INVESTIGATOR_75144], literature, or other data, then this will be 
submitted and reported in accordance with [COMPANY_007]’s safet y reporting requirements.  Aggregate 
analyses of sa fety data will be performed on a regular basis per internal standard operating 
procedures .  
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 608.4.2. Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  [CONTACT_20023]) are termed “t olerators,” while those who show transient liver injury , but adapt 
are termed “adaptors.”  In some patients, transaminase elevations are a harbinger of a more 
serious potential outcome.  These patients f ail to adapt and therefore are “ susceptible” to 
progr essive and serious liver injury , commonly  referred to as drug induced liver injury  
(DILI).  Patients who experience a transaminase elevation above 3 times the upper limit of 
normal (× ULN) should be monitored more frequently  to determine if they are an “ad aptor” 
or are “susceptible.”
In the majority  of DILI cases, elevations in aspartate aminotransferase (AST) and/or alanine 
aminotransferase (ALT) precede total bilirubin (TBili) elevations (>2 × ULN) b y several 
days or weeks.  The increase in TBili ty pi[INVESTIGATOR_1306] y occurs while AST/ALT is/are still elevated 
above 3 × ULN (ie, AST/AL T and TBili values will be elevated within the same lab sample).  
In rare instances, b y the time TBili elevations are detected, AST/ALT values might have 
decreased.  This occurrence is still regarded as a potential DILI.  Therefore, abnormal 
elevations in either AST OR AL T in addition to TBili that meet the criteria outlined below 
are considered potential DILI (assessed per Hy ’s law criteria) cases and should alway s be 
considered important medical events, even before all other possible causes of liver injury  
have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the patient’s 
individual baseline values and underl ying conditions.  Patients who pre sent with the 
following laboratory  abnormalities should be evaluated further as potential DILI (Hy ’s law) 
cases to definitivel y determine the etiology of the abnormal laboratory  values:
Patients with AST/AL T and TBili baseline values within the normal rang e who 
subsequently  present with AST OR ALT values >3 ×ULN AND a TBili value 
>2× ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available;
For patients with baseline AST OR ALT OR TBili values above the ULN, the 
follow ing threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 × ULN; or >8 × ULN (whichever is 
smaller);
Preexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at least 1 × ULN or if the value reaches >3 ×ULN 
(whichever is smaller).
Rises in AST/AL T and TBili separate d by [CONTACT_726] a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor. 
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, [ADDRESS_532624] and ALT and TBili, laboratory  tests should 
include albumin, creatine kinase (CK), direct and indirect bilirubin, gamma glutamy l 
transferase (GGT), prothrombin time (PT)/international normalized ratio (INR), total bile 
acids, alkaline phosphatase and acetaminophen drug and/or protein adduct levels.  
Consideration should also be given to drawing a separate tube of clotted blood and an 
anticoagulated tube of blood for further testing, as needed, for further contemporaneous 
analyses at the time of the recognized i nitial abnormalities to determine etiology .  A detailed 
history , including relevant information, such as review of ethanol, acetaminophen (either b y 
itself or as a coformulated product in prescription or over the counter medications), 
recreational drug, su pplement (herbal) use and consumption, family  history , sexual history , 
travel history , history  of contact [CONTACT_4490] a jaundiced person, surgery , blood transfusion, history  
of liver or allergic disease, and potential occupational exposure to chemicals, should be
collected.  Further testing for acute hepatitis A, B, C, D, and E infection and liver imaging 
(eg, biliary  tract) may  be warranted. 
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili elevation defined above s hould be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet been found.  Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability  of all the results of the 
investigations per formed to determine etiology  of the L FT abnormalities. 
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have excluded an alternative etiology .
8.4.3. Potential VOD/SOS Cases
All cases of VOD/SOS with or without previous HSCT, regardless of causality  and severit y 
must be reported as an SAE for entire study  duration of 12 months from enrollment, 
regardless of subsequent anticancer therapy (eg, consolidation and/or conditioning regim en, 
or HSCT). 
The assessment and management of VOD/SOS will be up to phy sician’s discretion and per 
institutional standards of practice.  All the assessments and management (eg, prophy laxis 
and/or treatment) should be recorded in the CRF.  In this stud y, the diagnosis of VOD/SOS is 
as described in Section 7.4.[ADDRESS_532625] under study  during pregnancy  or breastfeeding and 
occupational exposure are reportable to [COMPANY_007] Safety  within 24 hours of investigator 
awareness.
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Exposure During Pregnancy
For both unapproved/unlicensed products and for marketed products, an exposu re during 
pregnancy  (EDP) occurs if:
A female becomes, or is found to be, pregnant either while receiving or having been 
exposed (eg, because of treatment or environmental exposure) to the investigational 
product; or the female becomes or is found to be pr egnant after discontinuing and/or 
being exposed to the investigational product.
An example of environmental exposure would be a case involving direct contact [CONTACT_4490] 
a [COMPANY_007] product in a pregnant woman (eg, a nurse reports that she is pregnant and has 
been e xposed to chemotherapeutic products).
A male has been exposed (eg, because of treatment or environmental exposure) to the 
investigational product prior to or around the time of conception and/or is exposed 
during his partner’s pregnancy . 
If a patient or p atient’s partner becomes or is found to be pregnant during the 
patient’s treatment with the investigational product, the investigator must report this 
information to [COMPANY_007] Safety  on the CT SAE Report Form and an EDP supplemental 
form, regardless of whethe r an SAE has occurred.   In addition, the investigator must 
submit information regarding environmental exposure to a [COMPANY_007] product in a 
pregnant woman (eg, a patient reports that she is pregnant and has been exposed to a 
cytotoxic product by  [CONTACT_4691][INVESTIGATOR_4598]) to [COMPANY_007] Safet y using the EDP 
supplemental form.  This must be done irrespective of whether an AE has occurred 
and within 24 hours of awareness of the exposure.  The information submitted should 
include the anticipated date of delivery  (see belo w for information related to 
termination of pregnancy).
Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome.  The investigator will follow the pregnancy  until 
completion (or unti l pregnancy  termination) and notify  [COMPANY_007] Safet y of the outcome as a 
follow -up to the initial EDP supplemental form.  In the case of a live birth, the structural 
integrity  of the neonate can be assessed at the time of birth.  In the event of a termination , the 
reason(s) for termination should be specified and, if clinically  possible, the structural 
integrity  of the terminated fetus should be assessed by  [CONTACT_4692] (unless 
pre-procedure test findings are conclusive for a congenital anomal y and the findings are 
reported).
If the outcome of the pregnancy  meets the criteria for an SAE (ie, ectopic pregnancy , 
spontaneous abortion, intrauterine fetal demise, neonatal death, or congenital anomal y [in a 
live-born bab y, a terminated fetus, an intrauterine fetal demise, or a neonatal death]), then the 
investigator should follow the procedures for reporting SAEs.
Additional information about pregnancy  outcomes that are reported to [COMPANY_007] Safet y as SAEs 
follows: 
Spontaneous abortion includes miscarriage an d missed abortion.
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 63Neonatal deaths that occur within [ADDRESS_532626].
Additional information regarding the EDP may  be requested by  [CONTACT_456].  Further 
follow -up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to iden tify developmental delay s).  In the case of paternal exposure, 
the investigator will provide the patient with the Pregnant Partner Release of 
Information Form to deliver to his partner.  The investigator must document in the 
source documents that the patie nt was given the Pregnant Partner Release of 
Information Form to provide to his partner.
[IP_ADDRESS]. Exposure During Breastfeeding
Scenarios of exposure during breastfeeding must be reported, irrespective of the presence of 
an associated SAE, to [COMPANY_007] Safet y within 2 4hours of the investigator’s awareness, using the 
CT SAE Report Form.  An exposure during breastfeeding report is not created when a [COMPANY_007] 
drug specifically  approved for use in breastfeeding women (eg, vitamins) is administered in 
accord with authorized use.  However, if the infant experiences an SAE associated with such 
a drug’s administration, the SAE is reported together with the exposure during breastfeeding.
[IP_ADDRESS]. Occupational Exposure
An occupational exposure occurs when, during the performance of job dut ies, a person 
(whether a healthcare professional or otherwise) gets in unplanned direct contact [CONTACT_8898], which may  or may  not lead to the occurrence of an AE.
An occupational exposure is reported to [COMPANY_007] Safety  within 24 hours of the investigator’s 
awareness, using the CT SAE Report Form, regardless of whether there is an associated 
SAE.  Since the information does not pertain to a patient enrolled in the study , the 
information is not recorded on a CRF; however, a copy  of the completed CT SAE Rep ort 
Form is maintained in the investigator site file.
8.4.5. Medication Errors
Other exposures to the investigational product under study  may  occur in clinical trial settings, 
such as medication errors. 
Safety Event Recorded on the CRF Reported on the CT SAE 
Report Form to [COMPANY_007] Safety 
Within 24 Hours of Awareness
Medication errors All (regardless of whether 
associated with an AE)Only  if associated with an SAE
Gemtuzumab Ozogamicin (MYLOTARG ™)
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Medication Errors
Medication errors may result from the administration or consumption of the investigational 
product by [CONTACT_4670], or at the wrong time, or at the wrong dosage strength. 
•Medication errors include:
•Medication errors involving patient exposure to the investigational product;
•Potential medication errors or uses outside of what is foreseen in the protocol that 
do or do not involve the participating patient.
Such medication errors occurring to a study participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified immediately.Whether or not the medication error is accompanied by [CONTACT_1149], as determined by [CONTACT_1275], the medication error is recorded on the medication error page of the CRF and, if 
applicable, any associated AE(s), serious and non-serious, are recorded on an AE page of the CRF.
Medication errors should be reported to [COMPANY_007] Safety within [ADDRESS_532627] SAE Report 
Form only when associated with an SAE .
9. DATA ANALYSIS/STATISTICAL METHODS
Detailed methodology for summary and statistical analyses of the data collected in this study 
is outlined here and further detailed in a statistical analysis plan (SAP), which will be maintained by [CONTACT_456].  The SAP may modify what is outlined in the protocol where appropriate; however, any major modifications of the primary endpoint definitions or their analyses will also be reflected in a protocol amendment.
9.1. Sample Size Determination
The QTc analysis will be based on a non-inferiority hypothesis testing framework. 
If the upper bounds of one-sided 95% confidence intervals of change from baseline in QT 
measurements using Fridericia’s heart rate correction for each of the QTc sampling time points (Day 4, 0 hours, and Day 7, at 0, 2, 4 and 6 hours) are below [ADDRESS_532628]-baseline dose QTc interval will be considered to be “non-inferior” to the baseline; the QTc effect of GO will be concluded to be not unacceptable.
Thus with an overall 1-sided significance level of 0.[ADDRESS_532629] deviation of 18.8 msec and a mean change from baseline for QTcF up to 10 msec, 50 patients will provide 90 % power for assessing the 5 QTc sampling timepoints using paired difference in means with the t distribution.  
 
 
CCI
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 65If the upper bounds of one -sided 95% confidence intervals of change from baseline in QT 
measurements using Fridericia’s heart rate correct ion for each of the QTc sampling time 
points (on Day  4, at 0 hours, and Day  7, at 0, 2, 4, and 6 hours) are below [ADDRESS_532630]-
baseline dose QTc interval will be considered to be “non -inferior” to the baseline.
The inclusion of [ADDRESS_532631] 1 dose of study  
medication.  The safet y analysis set will be the primary anal ysis set for evaluating treatment 
administration/compliance and safet y.
9.2.3. QTc Analysis Set
The QTc analysis set will include all patients in the safet y analysis set who have a baseline 
ECG and at least one post- dose ECG. 
9.2.4. PK Analysis Set
All patients who are treated with GO and contribute at least one PK sample will be included 
in the PK analy sis set. 
9.2.5. PK/PD Analysis Set
QTc PKPD anal ysis set: All patients who are treated with GO and contribute at least one PK 
sample who have a baseline ECG and at least one post -dose ECG.
Safety  and Efficacy  PKPD anal ysis set: All patients who are treated with GO and con tribute 
at least one PK sample.
9.3.Planned Analyses
Separate summaries for adult and pediatric patients will be presented. Combined summaries 
of adult and pediatric patients will also be presented.
9.3.1. Analysis of Primary Endpoint 
ECG measurements from the ECG c ore laboratory (an average of the triplicate 
measurements) will be used for the statistical analysis and all data presentations.  Only  the 
scheduled ECGs will be used in the primary  analysis.  The last available planned triplicate 
measurements prior to fir st dose will be used as baseline.
Gemtuzumab Ozogamicin (MYLOTARG ™)
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 66QT measurements will be corrected by [CONTACT_4701] (QTc) including Bazzett’s (QTcB) and 
Fridericia’s (QTcF) methods, and a study-specific correction method (QTcS) will be evaluated according to the observed data.  QTcF will be used for the primary analysis. 
The absolute corrected QT interval and changes in QTc (QTcB, QTcF, and/or QTcS) from 
baseline will be summarized using descriptive statistics by [CONTACT_4702]. 
A random effect model with the nominal timepoints as a fixed effect and patients as a 
random effect will be used for the primary analysis to estimate the mean change in QTcF (primary endpoint) at the post baseline nominal timepoints (Day 4, 0 hours, and Day 7, at 0, 2, 4 and 6 hours) along with 2-sided 90% confidence interval for the mean.  The maximum increase in QTc from baseline will be computed over all time points.  The maximum increase from baseline will be summarized with descriptive statistics. 
Categorical analysis of changes in QTc (QTcB, QTcF, and/or QTcS) from baseline including 
absolute QTc interval prolongation and maximum increase will be provided.  Interval measurements from unscheduled ECGs will be included in the categorical analyses.
Baseline versus worst on treatment QTc according to maximum CTCAE grade will be 
summarized using a shift table.
9.3.2. Analysis of Secondary Endpoints
[IP_ADDRESS]. Safety Analysis9.[IP_ADDRESS]. Adverse Events
AEs will graded by [CONTACT_421946] 4.03 and coded using 
the Medical Dictionary for Regulatory Activities (MedDRA).  The focus of AE summaries will be on Treatment Emergent Adverse Events, those with initial onset or increasing in severity after the first dose of study medication.  The number and percentage of patients who experienced any AE, SAE, treatment related AE, and treatment related SAE will be summarized according to worst toxicity grades.  
[IP_ADDRESS].2. Laboratory Test Abnormalities
The number and percentage of patients who experienced laboratory test abnormalities will be 
graded according to CTCAE version 4.[ADDRESS_532632]. 
For laboratory tests without CTCAE grade definitions, results will be categorized as normal, 
abnormal, or not done.
For patients who respond, time to neutrophil recovery (>500/ μl) and time to platelet recovery 
(>50,000/ μl) will be summarized using Kaplan-Meier methods.CCI
Gemtuzumab Ozogamicin (MYLOTARG ™)
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page [IP_ADDRESS].3. Deaths 
The number of deaths (and the cause of death) during the study periods will be summarized.
[IP_ADDRESS].4. VOD/SOS
Incidence and timing of VOD/SOS and HSCT will be summarized.
[IP_ADDRESS]. Pharmacokinetic Analysis
These analyses will be conducted in the PK analysis set.
The pharmacokinetics of three analytes will be measured in patient samples in this study: 
total hP67.6 antibody, conjugated calicheamicin, and unconjugated calicheamicin.  The primary analyte representing GO PK is the total hP67.6 antibody.  Noncompartmental analysis (NCA) will be performed to characterize the clearance and volume of distribution of total hP67.6 antibody following the fractionated regimen (secondary endpoint). 
Population PK analysis, using nonlinear mixed effects modeling methodology as 
implemented in NONMEM
®Version 7.3.0 (ICON Development Solutions, Ellicott City,
MD), will also be conducted and reported separately.  A population modeling approach will be used to further characterize the PK of total hP67.6 antibody, conjugated calicheamicin, and unconjugated calicheamicin, as well as to assess intrinsic and extrinsic covariates that may account for some of the interindividual variability of population PK parameters. 
[IP_ADDRESS]. Pharmacokinetic/Pharmacodynamic (PK/PD) Analysis
Population PK/PD modeling analyses will be explored, as necessary, based on emerging 
safety/clinical response data.  The results of these population modeling analyses will be reported separately from the clinical study report.
 
[IP_ADDRESS]. QTc-Concentration Analysis
Concentration data of total hP67.6 antibody and unconjugated calicheamicin (if feasible) will 
be listed by [CONTACT_421947].
The relationship between observed drug concentration (total hP67.6 antibody and 
unconjugated calicheamicin) to changes in QT/QTc will be evaluated to further characterize the effect on QT interval.  QTc- concentration- analysis will be conducted using linear regression, ie, a linear mixed effects model.  If appropriate, other models may also be examined.  Exploratory analyses (via graphical displays and/or model fitting) may include accounting for a delayed effect and the justification for the choice of pharmacodynamics model.  Diagnostic evaluation will be included to explore the adequacy of the model.  The results of these modeling analyses may be reported separately from the clinical study report.
3CCI
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Immunogenicity
The percentage o f patients with positive ADA and neutralizing antibodies will be 
summarized.  For patients with positive ADA and neutralizing antibodies, the magnitude 
(titer), time of onset, and duration of ADA response will also be described, as data permit.  I n 
additio n, potential effects of ADA formation on the PK profile of GO will be examined 
individually , and evaluated between the groups with and without positive ADA.
Because the observed incidence of ADA is highly  dependent on multiple factors including 
the assay s used for ADA detection, timing of sample collection and immune status of the 
patients, the incidence of ADA observed in the planned stud y ma y differ from the incidence 
reported in historical clinical trials.
These analy ses will be conducted in the Safet y Analysis Set.
Samples will be analy zed for ADAs using a tiered approach of screening, confirmation, and 
titer determination. Samples that test positive for ADA will be further characterized to 
determine whether neutralizing antibodies (NAb) are present.
[IP_ADDRESS]. Eff icacy Analyses 
Efficacy  evaluation anddetermination of remission status by  [CONTACT_421925][INVESTIGATOR_1516] (and biops y if applicable) will be conducted at the end of each cycle using 
European Leukemia Net (ELN 2017) recommendations (see Section 7.5 ).  Survival status for 
each patient will be collected for the stud y duration of 12 months. 
[IP_ADDRESS].1. Response
The proportion of the patients who respond (CR + CRi [CR with incomplete hematologic 
recovery ] according to best respo nse) and a 95% confidence interval will be reported. 
[IP_ADDRESS].2. Overall Survival 
Overall survival rate at 12 months with a 95% confidence interval will be estimated using 
Kaplan Meier methods and presented graphicall y. 
9.4. Interim Analysis
No formal interim anal ysis will be conducted for this study .  However, as this is an 
open -label stud y, the sponsor may conduct unblinded reviews of the data during the course of 
the study  for the purpose of safet y assessment, facilitating dose -escalation decisions, 
facilitating pharm acokinetic (PK)/pharmacod ynamic (PD) modeling, and/or to support 
clinical development. 
9.5.Data Monitoring Committee 
This study  will not use a data monitoring committee. 
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, [ADDRESS_532633] to ensure that 
the protocol and Good Clinical Practices (GCPs) are being followed.  The monitors may  
review source documents to confirm that the data recorded on CRFs are accurate.  The 
investigator and institution will allo w [COMPANY_007] monitors/auditors or its agents and appropriate 
regulatory  authorities direct access to source documents to perform this verification.  This 
verification may  also occur after study  completion.
During study  conduct and/or after study  completion, th e investigator site may  be patient to 
review b y the IRB/EC, and/or to quality  assurance audits performed by  [CONTACT_4618], or companies 
working with or on behalf of [COMPANY_007], and/or to inspection by  [CONTACT_8901].
The investigator(s) will notif y [COMPANY_007] or its agents immediately of an y regulatory inspection 
notification in relation to the study .  Furthermore, the investigator will cooperate with [COMPANY_007] 
or its agents to prepare the investigator site for the inspection and will allow [COMPANY_007] or its 
agent, whenever feasible, to be present during the inspection.  The investigator site and 
investigator will promptly resolve an y discrepancies that are identified between the stud y 
data and the patient's medical records.  The investigator will promptly  provide copi[INVESTIGATOR_74040].  Before response submission to the regulatory 
authorities, the investigator will provide [COMPANY_007] or its agents with an opportunity  to review 
and comment on responses to any  such findings.
It is important that the investigator(s) and their relevant personnel are available during the 
monitoring visits and possible audits or inspections and that sufficient time is devoted to the 
process.
11.DATA HANDLING AND RE CORD KEEPI[INVESTIGATOR_1645]
11.1. Case Report Forms/Electronic Data Record
As used in this protocol, the term CRF should be understood to refer to either a paper form 
oran electronic data record or both, depending on the data collection method used in this 
study .
A CRF is required and should be completed for each included patient.  The completed 
original CRFs are the sole propert y of [COMPANY_007] and should not be made available in any form to 
third parties, except for authorized representatives of [COMPANY_007] or appropriate regulatory  
authorities, without written permission fro m [COMPANY_007].  The investigator shall ensure that the 
CRFs are securel y stored at the study  site in encrypted electronic form and will be password 
protected to prevent access by  [CONTACT_20011].
The investigator has ultimate responsibility  for the c ollection and reporting of all clinical, 
safet y, and laboratory data entered on the CRFs and any other data collection forms (source 
documents) and ensuring that they are accurate, authentic/original, attributable, complete, 
consistent, legible, timely  (contemporaneous), enduring, and available when required.  The 
CRFs must be signed by  [CONTACT_421948] (MYLOTARG )
B1761031
Protocol, [ADDRESS_532634] be dated, initialed, and explained (if necessary ) and should not obscure the 
original entry . 
In most cases, the source documents are the hospi[INVESTIGATOR_421921].  In these 
cases, data collected on the CRFs must match the data in those c harts. 
In some cases, the CRF may  also serve as the source document.  In these cases, a document 
should be available at the investigator site and at [COMPANY_007] that clearl y identifies those data that 
will be recorded on the CRF, and for which the CRF will sta nd as the source document.
11.2. Record Retention
To enable evaluations and/or inspections/audits from regulatory authorities or [COMPANY_007], the 
investigator agrees to keep records, including the identity  of all participating patients 
(sufficient information to link records, eg, CRFs and hospi[INVESTIGATOR_1097]), all original signed 
informed consent/assent documents, copi[INVESTIGATOR_4600], safety  reporting forms, source 
documents, and detailed records of treatment disposition, and adequate documentation of 
relevant corresponde nce (eg, letters, meeting minutes, and telephone call reports).  The 
records should be retained by  [CONTACT_52248] I CH guidelines, according to 
local regulations, or as specified in the clinical study  agreement (CSA), whichever is longer.  
The investigator must ensure that the records continue to be stored securel y for so long as 
they are retained.
If the investigator becomes unable for an y reason to continue to retain study records for the 
required period (eg, retirement, relocation), Pfi zer should be prospectivel y notified.  The 
study  records must be transferred to a designee acceptable to [COMPANY_007], such as another 
investigator, another institution, or an independent third party  arranged by  [CONTACT_4618]. 
Investigator records must be kept for a m inimum of [ADDRESS_532635] obtain [COMPANY_007]'s written permission before disposing of an y records, 
even if retention requirements have b een met.
12.ETHICS
12.1. Institutional Review Board/Ethics Committee
It is the responsibility  of the investigator to have prospective approval of the study  protocol, 
protocol amendments, informed consent/assent documents, and other relevant documents, eg, 
recruitme nt advertisements, if applicable, from the I RB/EC.  All correspondence with the 
IRB/EC should be retained in the investigator file.  Copi[INVESTIGATOR_1309] I RB/EC approvals should be 
forwarded to [COMPANY_007].
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 71The only  circumstance in which an amendment may  be initiated prior to IRB/EC approval is 
where the change is necessary  to eliminate apparent immediate hazards to the patients.  In 
that event, the investigator must notify  the IRB/EC and [COMPANY_007] in writing immediately  after 
the implementation.
12.2. Ethical Conduct of the Study
The study  will be conducted in accordance with the protocol, legal and regulatory  
requirements, and the general principles set forth in the I nternational Ethical Guidelines for 
Biomedical Research Involving Human Subjects (Council for International Organiz ations of 
Medical Sciences 2002), ICH Guideline for Good Clinical Practice, and the Declaration of 
Helsinki.  I n addition, the study  will be conducted in accordance with applicable local 
regulatory  requirements and laws.
12.3. Patient Information and Consent
Allparties will comply  with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of patient personal data.  Such 
measures will include omitting patient names or other directl y identifi able data in an y 
reports, publications, or other disclosures, except where required b y applicable law. 
The personal data will be stored at the study  site in encry pted electronic and/or paper form 
and will be password protected or secured in a locked room to ensure that only  authorized 
study  staff have access.  The study  site will implement appropriate technical and 
organizational measures to ensure that the personal data can be recovered in the event of 
disaster.  In the event of a potential personal data breach, the study  site shall be responsible 
for determining whether a personal data breach has in fact occurred and, if so, providing 
breach notifications as required by  [CONTACT_2371].
To protect the rights and freedoms of natural persons with regard to the processi ng of 
personal data, when study  data are compi[INVESTIGATOR_168024], patient names will be removed and will be replaced b y a single, specific, numerical 
code, based on a numbering sy stem defined by  [CONTACT_4618].  All other ident ifiable data transferred 
to [COMPANY_007] or other authorized parties will be identified by  [CONTACT_20007], subject- specific code.  
The investigator site will maintain a confidential list of patients who participated in the study , 
linking each patient’s numerical co de to his or her actual identity .  In case of data transfer, 
[COMPANY_007] will maintain high standards of confidentiality  and protection of patients’ personal data 
consistent with the Clinical Study  Agreement and applicable privacy  laws.
The informed consent/assent documents and an y patient recruitment materials must be in 
compliance with ICH GCP, local regulatory  requirements, and legal requirements, including 
applicable privacy  laws.
The informed consent/assent documents used during the informed consent process and any  
patient recruitment materials must be reviewed and approved b y [COMPANY_007], approved b y the 
IRB/EC before use, and available for inspection.
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, [ADDRESS_532636] ensure that each study  patient, or his or her legall y acceptable 
representative, is fully  informed about the nature and objectives of the study , the sharing of 
data relating to the stud y , the sharing of data relating to the study   and possible risks 
associated with participation, including the risks associated with the processing of the 
patient’s personal data.  The investigator further must ensure that each study  patient, or his or 
her legall y acceptable representative, or parent(s) or legal guardian if a minor, is fully 
informed about his or her right to access and correct his or her perso nal data and to withdraw 
consent for the processing of his or her personal data. 
Whenever consent is obtained from a patient’s legally  acceptable representative, the patient’s 
assent (affirmative agreement) must subsequently be obtained when the patient h as the 
capacity  to provide assent, as determined by  [CONTACT_1201]/EC.  If the investigator determines that 
a patient’s decisional capacity is so limited he/she cannot reasonabl y be consulted, then, as 
permitted by  [CONTACT_1201]/EC and consistent with local regulatory  and legal requirements, the 
patient’s assent may  be waived with source documentation of the reason assent was not 
obtained.  If the stud y patient does not provide his or her own consent, the source documents 
must record wh y the patient did not provide cons ent (eg, decisionall y impaired adult), how 
the investigator determined that the person signing the consent was the patient’s legally  
acceptable representative, the consent signer’s relationship to the study  patient (eg, parent, 
spouse), and that the patien t’s assent was obtained or waived.  If assent is obtained verball y, 
it must be documented in the source documents.  
If the stud y includes minor patients who reach the age of majorit y during the study, as 
recognized under local law, they  must reconsent as adults to remain in the study .  If the 
enrollment of emancipated minors is permitted by  [CONTACT_74100], the I RB/EC, and 
local law, they  must provide documentation of legal status to give consent without the 
permission of a parent or legal guardian.   
The investigator, or a person designated b y the investigator, will obtain written informed 
consent from each patient or the patient's legally acceptable representative and the patient’s 
assent, when applicable, before an y stud y-specific activity  is perf ormed.  The investigator 
will retain the original of each patient's signed consent/assent document.
12.4. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the world, or if the investigator is aware of an y new 
information that might influence the evaluation of the benefits and risks of the investigational 
product, [COMPANY_007] should be informed immediately. 
In additi on, the investigator will inform [COMPANY_007] immediately  of any  urgent safet y measures 
taken b y the investigator to protect the study patients against any immediate hazard, and of 
any serious breaches of this protocol or of ICH GCP that the investigator becomes aware of.
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, [ADDRESS_532637] been recruited and completed the study  as 
stated in the regulatory  application (ie, clinical trial application [CTA]) and ethics application 
in the Member State.  Poor recruitment (recruiting less than the anticipated number in the 
CTA) by  a Member State is not a reason for premature termination but i s considered a 
normal conclusion to the study  in that Member State.
13.2. End of Trial in All Other Participating Countries 
End of trial in all other participating countries is defined as last patient last visit (L PLV). 
14.SPONSOR DISCONTINUAT ION CRITERIA
Premature termination of this study  may  occur because of a regulatory  authority  decision, 
change in opi[INVESTIGATOR_1100]/EC, or investigational product safety  problems, or at the 
discretion of [COMPANY_007].  In addition, [COMPANY_007] retains the right to discontinue developmen t of GO at 
any time.
If a stud y is prematurel y terminated, [COMPANY_007] will promptly  notify  the investigator.  After 
notification, the investigator must contact [CONTACT_266538][INVESTIGATOR_4601]  
(if applicable) within [ADDRESS_532638] extent possible.
15.PUBLICATION OF STUDY RESULTS
15.1. Communication of Results by [CONTACT_74101].clinicaltrials.gov (ClinicalTrials.gov), the European Clinical Trials 
Database (EudraCT), and/or www.pfizer.com, and other public registries in accordance with 
applicable local laws/regulations. 
In all cases, stud y results are reported b y [COMPANY_007] in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the stud y or the country in 
which the study  was conducted.
www.clinicaltrials.gov
[COMPANY_007] posts clinical trial US Basic Results on www.clinicaltrials.gov for [COMPANY_007]- sponsored 
interventional studies (conducted in patients) that evaluate the safet y and/or efficacy of a 
[COMPANY_007] product, regardless of the geographical location in which the study  is conducted.  US 
Basic Results are submitte d for posting within 1 year of the primary completion date (PCD) 
for studies in adult populations or within 6 months of the PCD for studies in pediatric 
populations.
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, [ADDRESS_532639]
[COMPANY_007] posts European Union (EU) Basic Results on EudraCT for all [COMPANY_007] -sponsored
interventional studies that are in scope of EU requirements.  EU Basic Results are submitted 
for posting within 1 y ear of the PCD for studies in adult populations or within 6 months of 
the PCD for studies in pediatric populations.
www.pfizer.com
[COMPANY_007] posts Public Disclosure Sy nopses (clinical study  report sy nopses in which any  data 
that could be used to identify  individual patients has been removed) on www.pfizer.com for 
[COMPANY_007] -sponsored interventional studies at the same time the US Basic Results docume nt is 
posted to www.clinicaltrials.gov.
15.2. Publications by [CONTACT_110468] (PI) of the results of the study based on information collected or 
gene rated by  [CONTACT_978], whether or not the results are favorable to the [COMPANY_007] product.  However, 
to ensure against inadvertent disclosure of confidential information or unprotected 
inventions, the investigator will provide [COMPANY_007] an opportunity  to review any  proposed 
publication or other t ype of disclosure of the results of the study (collectively, “publication”) 
before it is submitted or otherwise disclosed.
The investigator will provide any  publication to [COMPANY_007] at least [ADDRESS_532640] publication is 
to be a joint publication covering all investigator sites, and that an y subsequent publications 
by [CONTACT_978] [INVESTIGATOR_110423].  However, if a joint manuscript has not 
been submitt ed for publication within 12 months of completion or termination of the study  at 
all participating sites, the investigator is free to publish separatel y, patient to the other 
requirements of this section.
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 75For all publications relating to the study , the in stitution will comply  with recognized ethical 
standards concerning publications and authorship, including Section II -“Ethical 
Considerations in the Conduct and Reporting of Research” of the Uniform Requirements for 
Manuscripts Submitted to Biomedical Jou rnals, http://www.icmje.org/index.html#authorship, 
established by  [CONTACT_4717].
Publication of study  results is also provided in the CSA between [COMPANY_007] and the institution.  I n 
this section entitled Publications by  [CONTACT_4718], the defined terms shall have the meanings 
assigned to them in the CSA.
If there is an y conflict between the CSA and its attachments to it, the terms of the CSA take 
precedence.  If there is any conflict between thi s protocol and the CSA, this protocol will 
take precedence as to an y issue regarding treatment of study  patients, and the CSA take 
precedence as to all other issues.
Gemtuzumab Ozogamicin (MYLOTARG ™)
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 7616. REFERENCES 
1. MYLOTARG ™(gemtuzumab ozogamicin) for injection, for intravenous use 
[prescribing information].  Philadelphia, PA: Wyeth Pharmaceuticals Inc., a subsidiary of [COMPANY_007] Inc.; 2017.
2. Castaigne S, Pautas C, Terre C, et al. Effect of gemtuzumab ozogamicin on survival of 
adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.  Lancet 2012; 379(9825):1508-16.
3. Guidance for industry: E14 clinical evaluation of QT/QTc interval prolongation and 
proarrhythmic potential for non-antiarrhythmic drugs, US Department of Health and 
Human Services, Food and Drug Administration, Center for Drug Evaluation and 
Research (CDER).  https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073153.pdf. 
 
 
 
5. Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 
[ADDRESS_532641] recommendations from an international expert panel.  Blood 2017; 129(4):424-47.
6. Peiper SC, Ashmun RA, Look AT. Molecular cloning, expression, and chromosomal 
localization of a human gene encoding the CD33 myeloid differentiation antigen.  Blood 1988; 72(1):314-21.
7. Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab 
ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19(13):3244-54.
8. Hamann PR, Hinman LM, Hollander I, et al. Gemtuzumab ozogamicin, a potent and 
selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.  Bioconjug Chem 2002; 13(1, Jan-Feb):47-58.
9. Cancer Stat Facts: Leukemia - Acute Myeloid Leukemia (AML), SEER Cancer 
Statistics Review, the National Cancer Institute of the National Institutes of Health 2017.  https://seer.cancer.gov/statfacts/html/leuks.html.
10. Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine 
vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.  Blood 2015; 126(3):291-9. C
CI
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 7711. an der Velden VHJ, te Mervelde JG, Hoogeveen PG, et al. Targeting of the CD33 -
calicheamicin immunoconjugate My lotarg (CMA -676) in acute m yeloid leukemia: in 
vivo and in vitro saturat ion and internalization by  [CONTACT_421949] m yeloid cells.  
Blood 2001; 97(10):3197 -204.
12. van der Velden VHJ, van Dongen JJM. Effectiveness of gemtuzumab ozogamicin 
(Mylotarg) treatment: cellular and s ystemic determinants.  EJHP Science 2006; 
12(6):118-122.
13. U.S. Department of Health and Human Services, Food and Drug Administration, 
Oncologic Drugs Advisory  Committee Briefing Document, My lotarg, 11 July  2017. 
https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Dr
ugs/OncologicDrugsAd visory Committee/UCM566015.pdf.
14. Taksin AL, Legrand O, Raffoux E, et al. High efficacy  and safet y profile of fractionated 
doses of My lotarg as induction therapy  in patients with relapsed acute m yeloblastic 
leukemia: a prospective study  of the alfa group.  Leukemia 2007; 21(1):66 -71.
15. Bross PF, Beitz J, Chen G, et al. Approval summary : Gemtuzumab ozogamicin in 
relapsed acute m yeloid leukemia.  Clin Cancer Res 2001; 7(6):1490 -1496.
16. Larson RA, Sievers EL, Stadtmauer EA, et al. Final report of the efficacy  and saf ety of 
gemtuzumab ozogamicin (My lotarg) in patients with CD33 -positive acute my eloid 
leukemia in first recurrence. Cancer 2005; 104([ADDRESS_532642] 1):1442-52.
17. Cheson BD, Bennett JM, Kopeck y KJ, et al. Revised recommendations of the 
International Working Group for Diagnosis, Standardization of Response Criteria, 
Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute My eloid 
Leukemia.  J Clin Oncol 2003; 21(24):4642 -9.
18. Guidance for Industry : Population pharmacokinetics. U.S. Department of Health a nd 
Human Services, Food and Drug Administration, Center for Drug Evaluation and 
Research (CDER). Center for Biologics Evaluation and Research (CBER). Feb 1999: 34 
pages. https://www.fda.gov/downloads/drugs/guidances/UCM072137.pdf.
19. Centers for Disease Contr ol and Prevention. A comprehensive immunization strateg y to 
eliminate transmission of hepatitis B virus infection in the [LOCATION_002]: 
recommendations of the Advisory  Committee on Immunization Practices (ACI P); 
Part1: immunization of infants, children, a nd adolescents.  MMWR 2005; 
54(RR- 16):1-34.
20. Getchell JP, Wroblewski KE, DeMaria A Jr, et al. Testing for HCV infection: an update 
of guidance for clinicians and laboratorians. MMWR Morb Mortal.  Wkly  Rep 2013; 
62(18):362-5.
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, [ADDRESS_532643] F, Abecassis M, et al. Revised diagnosis and severit y criteria for 
sinusoidal obstruction syndrome/veno- occlusive disease in adult patients: a new 
classification from the European Societ y for Blood and Marrow Transplantation.  Bone 
Marrow Transplant 2016; 51(7):906 -12.
22. Corbacioglu S, Carreras E, Ansari M, et al. Diagnosis and severit y criteria for sinusoidal 
obstruction sy ndrome/veno -occlusive disease in pediatric patients: a new classification 
from the European society for blood and marrow transplantation.  Bone Marrow 
Transplant. 2018 Feb;53(2):138-145.
23. Amadori S, Suciu S, Selleslag D, et al. Gemtuzumab Ozogamicin Versus Best 
Supportive Care in Older Patients With Newly  Diagnosed Acute My eloid Leukemia 
Unsuitable for Intensive Chemotherap y: Results of the Randomized Phase III 
EORTC -GIMEMA AML -19 Trial.  J Clin Oncol. 2016 Mar 20; 34(9):972-9.
Gemtuzumab Ozogamicin (MYLOTARG ™)
B1761031
Protocol, [ADDRESS_532644] clinical trial
CTA clinical trial application
CTCAE Common Terminology Criteria for Adverse Events
DFS disease free survival
DILI drug-induced liver injury
DMH dimethylhydrazideCCI
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, [ADDRESS_532645] European Clinical Trials Database
FACS flow activated cell sorting
FDA Food and Drug Administration
FSH follicle -stimulating hormone
GCP Good Clinical Practice
GGT gamma -glutamy l transferase
GIMEMA Gruppo Italiano Malattie EMatologiche dell'Adulto
GO gemtuzumab ozogamicin
GVHD graft -versus- host disease
hCG human chorionic gonadotropin
HCV hepatitis C virus 
HCV RNA Quantitative hepatitis C virus RNA measurement
hERG human ether -a-go-go- related gene
HIV human immunodeficiency  virus
HRQL health- related quality  of life
HSCT hematopoietic stem cell transplantation
IB investigator’s brochure
ICD informed consent document
ICH International Conference on Harmonisation
ID identification
IEC Independent Ethics Committee
Ig immunoglobulin
IHC immunohistochemistry
IND investigational new drug application
INR international normalized ratio
IP investigational product
IRB institutional review board
IRC internal review committee
IRT interactive response technology
IUD intrauterine device
IV intravenous
Gemtuzumab Ozogamicin (MYLOTARG ™)
B1761031
Protocol, [ADDRESS_532646] visit 
MedDRA Medical Dictionary for Regulatory Activities
MRI magnetic resonance imaging
msec millisecond 
N/A not applicable
NAb neutralizing antibodies
NCA non compartmental analysis
NCI National Cancer Institute
OS overall survival
PCD primary completion date
PD Pharmacodynamics(s)
PE physical examination
PI [INVESTIGATOR_421922] a study-specific heart rate correction method 
RBC red blood cells
RNA ribonucleic acid
SAE serious adverse event
SAP statistical analysis plan
SOP standard operating procedure
SOS sinusoidal obstruction syndrome
SRSD single reference safety document
S[LOCATION_003]R suspected unexpected serious adverse reaction
SWOG Southwest Oncology Group
TBili total bilirubin
TdP Torsades de Pointes
TEAEs treatment emergent adverse event
ULN upper limit of normal
US [LOCATION_002]
VOD veno-occlusive disease 
WBC white blood cellsCCI
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 82Appendix 2. Definition of Active Hepatitis Infection
Hepatitis B serological tests and definition of active infection.[ADDRESS_532647] outcomes Interpretation
HBsAg
anti-HBc
IgM anti -HBc
anti-HBspositive
positive
positive
negativeAcutely infected
HBsAg
anti-HBc
IgM anti -HBc
anti-HBspositive
positive
negative
negativeChronically infected
HBsAg: Hepatitis B surface antigen  
anti-HBs: Hepatitis B surface antibody 
anti-HBc: Total hepatitis B core antibody 
IgM anti -HBc: IgM antibody  to hepatitis B core antigen. 
Hepatitis C tests and Definition of active hepatitis C.[ADDRESS_532648] outcomes Interpretation
HCV antibody  
HCV RNAReactive
DetectedCurrent HCV infection
HCV antibody: antibody to hepatitis C virus
HCV RNA: Quantitative hepatitis C virus RNA measurement
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, 27 June 2018
PFIZER CONFIDENTIAL
Page 83Appendix 3.Laboratory Tests
Hem atology Panel Chemistry Panel Coagulation Panel Urinalysis
WBC/differential counts 
including blast
RBC count
Hem oglobin
Hem atocrit
Platelet countSodium
Potassium
Magnesium
Total calcium
Creatinine
Albumin
Alanine 
aminotransferase (ALT)
Aspartate 
aminotransferase (AST)
Glucose
Total Bilirubin 
Blood urea nitrogen 
(BUN) 
Uric acid or urate
Alkaline phosphat ase 
(ALK -P)
Lactate dehydrogenase 
(LDH)international normalized 
ratio/prothrombin time 
(INR/PT)
Activated Partial 
thromboplastin time 
(aPTT)
FibrinogenpH
Protein/albumin
Glucose
Blood/hemoglobin
Ketones/acetone
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, [ADDRESS_532649] of Drugs Known to Predispose to Torsades de Pointes
The medications which are known to be associated with a risk of TdP and known to prolong 
the QTc interval are listed in the CredibleMedsTdP risk category  
(https://www.crediblemeds.org). 
(CredibleMedsis associated with University of Arizona Cancer Center forEducation and
Research onTherapeutics [CERT]: “Torsades List:Drugs with aRisk ofTorsades de
Pointes,” Advisory Board).
Gem tuzumab Ozogamicin (MYLOTARG )
B1761031
Protocol, [ADDRESS_532650] ory and Relapsed AML (ELN 2017 
Recommendation)5
Refractory Disease: 
No complete remission (CR) or CR with incomplete hematologic recovery  (CRi) after 
2courses of intensive induction treatment; excluding patients with death in aplasia or 
death due to indeterminate cause. 
Relapse d Disease : 
After CR without minimal residual disease (CR MDR -), CR, or CRi, bone marrow 
blasts 5%; or reappearance of blasts in the blood; or development of extramedullary  
disease.